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Anamnesis, physical examination and laboratory testing are the pillars of the clinical 
diagnostic procedure. Alas, laboratory tests are not perfect and analytical errors happen, 
which can lead to misdiagnosis and detrimental consequences for patient care. 
Immunoassays are commonly used to measure various hormones and disease markers in 
patient samples. Despite decades of methodological development and technological 
advances, immunoassays used for clinical diagnosis are still associated with limitations 
and even some flaws. 
This thesis focuses on a long-lived immunoassay flaw that has been poorly researched 
in veterinary medicine. Humans and animals both carry heterophilic antibodies, also 
called anti-animal antibodies, in their circulation. These antibodies can interfere with 
immunoassays and cause erroneous results. The mechanism of action is the same for 
animals as it is for humans; the heterophilic antibodies bind to animal antibodies 
employed by the immunoassay, usually leading to a falsely increased measurement. Due 
to the extensive use of mouse IgG for analyte detection in immunoassays, anti-mouse 
antibodies are of particular concern. 
Herein, the prevalence of heterophilic antibodies against mouse IgG in a cohort of dog 
patients is estimated. It is demonstrated that the antibodies can have tangible 
consequences for patient care as they can interfere with commercial immunoassays used 
in veterinary laboratories. Falsely increased anti-Müllerian hormone (AMH) 
measurements were found, which could lead to needless surgery in dog patients. The 
molecular characteristics of canine heterophilic antibodies were shown to be 
heterogeneous. They may react with the Fc region or the Fab region of the murine IgG 
molecule. There is cross-reactivity with IgG from several species, and heterophilic 
antibodies in dogs are made up of the IgA, IgG and IgM isotypes. The prevalence of the 
antibodies varies between dog breeds, and the Bernese mountain dog is tentatively 
predisposed to heterophilic antibodies. The origin of these antibodies remains mostly 
unclear, but there is occasional cross-reactivity between antibodies to mouse IgG and 
canine autoantibodies to IgG. Canine heterophilic antibodies can persist for at least two 
years in serum and represent a risk factor for repeated analytical errors and misdiagnosis 
in patients with these antibodies.  
Keywords: antibodies, anti-mouse antibodies, autoantibodies, autoimmunity, canine, 
ELISA, immunoassay, immunotherapy, interference, rheumatoid factors 
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Abstract 
 
 
 
Laboratorietest utgör tillsammans med anamnes och klinisk undersökning grunden för 
all sjukdomsdiagnostik. Det finns dock brister hos alla laboratorietest, och det 
förekommer analytiska felkällor som kan leda till att patienter får fel diagnos och 
behandling. Immundiagnostik används ofta till att mäta hormoner och andra biomarkörer 
i patientprov. Trots decennier av metodutveckling och tekniska framsteg kvarstår dock 
grundläggande problem hos de immundiagnostiska metoder som används inom 
sjukvården. 
I denna avhandling undersöks en seglivad felkälla som endast har studerats sparsamt 
inom veterinärmedicin. Hos människor och djur förekommer anti-djurantikroppar, ofta 
kallade heterofila antikroppar, som kan störa immundiagnostiska metoder och orsaka 
felaktiga testresultat. Mekanismen är densamma oavsett djurslag; de heterofila 
antikropparna reagerar med testernas djurantikroppar, vilket oftast leder till falskt 
förhöjda mätningar. På grund av den utbredda användningen av mus-IgG i dessa test så 
utgör anti-musantikroppar ett särskilt stort problem inom immundiagnostik. 
Resultaten beskriver för första gången förekomsten av heterofila antikroppar mot mus-
IgG hos hundpatienter. Vidare demonstreras det att heterofila antikroppar hos hund kan 
ha påtaglig inverkan på patientsäkerheten, då de kan störa kommersiella immunanalyser 
som används av kliniska laboratorier. Felaktigt förhöjda mätningar av anti-müllerskt 
hormon (AMH) påvisades, vilket kan förorsaka onödiga kirurgiska ingrepp hos patienter. 
Heterofila antikroppar hos hund kan reagera med Fab- eller Fc-regionen hos mus-IgG. 
Det förekommer korsreaktivitet mot IgG från flera olika djurslag, och de heterofila 
antikropparna kan vara av IgA, IgG eller IgM-isotyp. Förekomsten av heterofila 
antikroppar varierar mellan hundraser, och berner sennenhundar är potentiellt 
predisponerade för dessa antikroppar. Antikropparnas ursprung har inte klarlagts, men 
det finns sporadisk förekomst av korsreaktivitet mellan autoantikroppar mot IgG och 
anti-musantikroppar. Heterofila antikroppar kan kvarstå i cirkulationen i åtminstone två 
år hos hundar, vilket är en riskfaktor för upprepade felaktiga mätningar och 
feldiagnostiseringar hos hundar med heterofila antikroppar. 
Nyckelord: antikroppar, autoantikroppar, autoimmunitet, ELISA, hund, 
immundiagnostik, immunterapi, interferens, reumatoida faktorer 
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1.1 Immunological assays 
 
The invention of the immunoassay marked a quantum leap forward for 
diagnostic medicine and research in many different fields. Immunoassays can 
detect and quantify minuscule amounts of specific molecules in complex 
biological samples. In clinical practice, this ability corresponds to the need for 
accurate measurement of biomarkers in patient samples. Endocrinology, 
reproduction, oncology, cardiology and many other branches of medicine are all 
heavily dependent on immunoassays for the diagnostic work-up of patients. 
There are several different variants of immunoassays, but the principle they all 
share is the binding between antibody and antigen. A standard immunoassay 
procedure for the detection of, for example, insulin is as follows: an anti-insulin 
antibody pulls down sample insulin to the bottom of a microtiter well. Another 
anti-insulin antibody, conjugated to a label (such as an enzyme) is added, also 
binding the insulin. Addition of a substrate to the enzyme produces a visible 
signal indicating the sample concentration of insulin. This immunoassay format, 
with two antibodies binding the antigen, is called an immunometric assay, and 
its use in clinical medicine and research is widespread. 
None of this would be possible if not for the remarkable specificity of 
affinity-matured antibodies. There are more antibody specificities in an 
individual than there are genes in the mammalian genomes – at least 50 million 
times as many according to estimates – and each one of these antibody 
specificities is prefabricated before the immune system is challenged with the 
specific antigen (Li et al., 2004). However, there are nuances to this picture, 
because antibodies are also versatile and can bind to many targets, including 
molecules that do not induce an immune response. They can even adhere to 
inanimate objects like plastic surfaces and magnetic beads (a prerequisite for the 
1 Introduction 
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immunoassay technology). It is therefore not surprising that unintended antibody 
interactions sometimes happen, and in laboratory testing, this can lead to 
analytical errors and misinterpretations, ultimately to the detriment of patient 
care. This phenomenon is called interference. It has been defined as “the effect 
of a substance present in the sample that alters the correct value of the result, 
usually expressed as concentration or activity, for an analyte” (Kroll & Elin, 
1994).  
Anti-animal antibodies in humans, also known as heterophilic antibodies, 
have been recognized as a source of immunoassay interference for nearly 50 
years, and several reports describe their impact on diagnosis and choice of 
treatment (Bolstad et al., 2013; Tate & Ward, 2004; Kricka, 1999). However, 
the understanding of the nature and origin of these antibodies is incomplete, and 
only a few publications document their existence in animals (Solter et al., 2008; 
Borromeo et al., 2007; Kashiwazaki & Thammasart, 1998). The topic of this 
thesis is immunoassay interference caused by endogenous anti-animal 
antibodies in dogs, and the main focus is on the immunometric assay format. 
1.2 A historical perspective on anti-animal antibody 
interference in immunoassays 
 
The history of immunoassay interference intertwines with the history of the 
immunoassay technology itself. Heated argumentation from the early 1900s 
demonstrates that interfering serum substances were a fertile source of debate in 
the early days of the Wassermann test, a predecessor of the modern 
immunoassay used for the diagnosing of syphilis (Seelman, 1918). Years later, 
the specific issue of interference from anti-animal antibodies coincided with the 
use of animal antibodies to detect analytes in serum. The immunoassay 
technology was first successfully implemented in 1959 by its inventors, 
Solomon Berson and Rosalyn Yalow when they used it to measure insulin in the 
circulation of humans (Yalow & Berson, 1959). For this purpose, they used anti-
insulin antibodies raised in guinea pigs. Reports that anti-animal antibodies 
could cause analytical errors first emerged in the early 1970s. The initial 
publication described anti-guinea pig-antibodies in human sera that interfered 
with measurements of hepatitis B antigen (Prince et al., 1973). In the space 
between these years, several improvements on the original immunoassay 
principle had already been made, including the “immunometric” or “non-
competitive” format, invented by Leif Wide in the late 1960s (Wide, 2005).  
Immunometric assays use two antibodies in combination – one to capture the 
analyte and the other to detect it. In this format, the signal is directly proportional 
13 
 
to the binding of the analyte to the detection antibody. In other words, the signal 
increases in parallel with the analyte concentration. The early immunoassay 
format as devised by Berson and Yalow is still in use, and these tests are 
commonly referred to as competitive assays. This term is not universally 
accepted, and they are also known as reagent limited assays. At any rate, the 
principle for this format is that only one analyte-specific antibody is used, but it 
interacts with two reagents: a labelled analyte, and the unlabelled analyte present 
in the sample. Thus, the signal is generated by immobilized antibodies that do 
not bind the unlabelled sample analyte. The signal in the competitive format is 
therefore inversely proportional to the analyte concentration; a high signal 
reflects low concentrations and vice versa. 
The ability of an assay to detect low concentrations of an analyte is referred 
to as its analytical sensitivity. In immunoassay analysis, analytical sensitivity is 
highly desirable as the objective often is to detect and quantify analytes present 
at low concentrations (Landegren et al., 2012). The directly proportional 
relationship between signal and concentration make immunometric assays vastly 
superior to competitive assays in terms of analytical sensitivity. The reason is 
that immunometric assays measure the specific signal against a low background. 
Competitive assays instead measure the difference between two large signals 
when the analyte concentration is low. The response at low concentrations is 
virtually indistinguishable from the response at zero (the absence of analyte) 
when both signals are large. These conditions lead to an analytical insensitivity 
with imprecise measurements at low analyte concentrations. The immunometric 
format improved both the analytical sensitivity and specificity of the test. The 
most sensitive immunometric assays are capable of detecting trace amounts of 
sample protein equaling a bucketful of chemicals scattered across all oceans on 
earth.  
The analytical specificity of an assay is its ability to distinguish a particular 
substance from other substances in a sample. Ultimately, the analytical 
specificity of an immunometric assay is contingent on the combination of 
antibodies used for capture and detection. If the two antibodies target two 
different epitopes on the same antigen, the risk for cross-reactivity is 
considerably lower than if only one epitope on the antigen is targeted. 
Immunometric assays are now by default used for measuring all analytes that 
are large enough to accommodate two antibodies, i.e. most proteins and peptides, 
but it is not a method without limitations. It soon became evident that these 
improvements on immunoassay performance also introduced a weakness – the 
susceptibility to interference from anti-animal antibodies. If a sample contains 
antibodies with affinity for animal antibodies, these might be capable of forming 
a bridge between the capture and the detection antibody, ostensibly reflecting 
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the presence of the analyte (Figure 1). However, this is an analytical error. 
Endogenous antibodies can also block the binding site on the immobilized 
antibody and cause negative interference, but this phenomenon has been much 
less investigated than positive interference. Previous immunoassay formats 
based on one antibody were less prone to antibody interference than 
immunometric assays because the specific reaction induced by the labelled 
analyte took precedence over the often weak, low-affinity reactions of the 
interfering antibodies. Unlike the competitive or reagent limited assays, the 
immunometric assays are reagent excess assays. In this format, the reaction is 
driven to completion, and even low-affinity reactions by low-concentration 
molecules can induce a signal. Although there are exceptions (Ghosh et al., 
2008), the absolute majority of reports on interference from endogenous 
antibodies regard immunometric two-site immunoassays (Bolstad et al., 2013). 
The immunometric format limited or solved several rather common issues with 
immunoassays, but as a trade-off, it aggravated the less common issue of 
antibody interference. 
 
 
 
Figure 1. Illustration of interference in immunometric assays. In the scenario to the left, there is no 
interference, and both the capture and detection antibodies bind the analyte. In the middle scenario, 
a heterophilic antibody has bound to the capture and detection antibodies, causing a falsely elevated 
result. In the scenario to the right, a heterophilic antibody blocks the capture antibody, causing a 
falsely decreased result (negative interference). Illustration by Camilla Bäckström. 
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In the mid-1970s, the hybridoma technology was developed (Kohler & Milstein, 
1975). Georges Köhler and César Milstein found that by fusing antibody-
producing B cells with immortal myeloma cells, monoclonal antibodies are 
producible in vitro for an extended (in theory, indefinite) period. However, this 
technique requires the acquisition of B cells from a “host” – a research animal 
immunized with the target antigen. Köhler and Milstein used mice for this 
purpose, and the mouse soon became the default host for these “magic bullets” 
– highly specific antibodies directed at a single antigen epitope. Monoclonal 
mouse antibodies had an enormous impact on many scientific fields, including 
immunodiagnostics. Up until this point, immunoassays had used polyclonal 
antibodies produced in various research animals, often guinea pigs or rabbits. 
Since polyclonal antibodies bind to multiple epitopes on the target antigen, 
problems with cross-reactivity were not uncommon, and the supply was limited 
to the capacity of the animal host for in vivo antibody production. The hybridoma 
technology enabled improved specificity and continuous production of large 
antibody quantities in vitro, so monoclonal mouse antibodies principally came 
to replace polyclonal antibodies for use in immunoassays. However, the use of 
monoclonal antibodies does not solve the problem with interference from anti-
animal antibodies, because this phenomenon is contingent on the structure of the 
immunoassay antibodies, and monoclonal and polyclonal antibodies are, in 
essence, structurally identical. Since immunoassay antibodies were now mainly 
derived from the mouse, the focus on interfering agents shifted to anti-mouse 
antibodies, and it turned out that these were very common in the human 
population, occurring in 40% of humans, according to an often-cited publication 
(Boscato & Stuart, 1986). In many cases, these antibodies appeared to be 
naturally occurring, or at any rate without a known source. Moreover, 
monoclonal mouse antibodies were also used as therapeutic drugs, so patients 
receiving therapeutic mouse antibodies acquired human anti-mouse antibodies 
(HAMAs) that interfered with immunoassays (Bolstad et al., 2013).  
There is now a plethora of case reports where immunoassay interference has 
affected the interpretation and treatment of clinical cases. Most of these reports 
concern anti-mouse antibodies, but there are also examples of patients with 
antibodies that react with rabbit, sheep or goat IgG, among others (Hennig et al., 
2000; Berglund & Holmberg, 1989; Hunter & Budd, 1980). Clearly, the broad 
spectrum of interfering agents, the variety of immunoassays available on the 
market and their widespread use are some of the factors that contribute to the 
frequent recurrence of the phenomenon, nearly 50 years after its first description. 
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1.3 Immunoassay interference from a veterinary 
perspective 
 
Immunoassays are as indispensable to the clinical practice of veterinary 
medicine as they are to human medicine. Although the veterinary analytes are 
not as plentiful as the human analytes, their use is frequent, and they serve as 
important prognostic and diagnostic markers. For example, the Clinical 
Pathology laboratory at the University Animal Hospital in Uppsala routinely 
analyzes approximately 20 different analytes with immunoassays, primarily in 
dog, cat and horse serum. These include thyroid hormones, glucocorticoid 
hormones and reproductive hormones, as well as peptide markers for cardiac 
disease and general inflammatory markers such as C-reactive protein (CRP). 
There is also a wide use of immunoassays for other analytes in veterinary 
research and surveillance of infectious diseases, which may have the potential 
for zoonotic transmission and economic impact in the livestock industry. 
Despite this, nearly all research that has been carried out in the field so far 
pertains to immunoassay interference in human samples and how it impacts the 
practice of human medicine. Much of the knowledge about immunoassay 
interference in humans could presumably apply to animals as well. Veterinary 
laboratories often use immunodiagnostic tests developed for use in humans to 
analyze animal specimens, and immunoassay kits that are species-specific 
include the same or similar reagents as their human counterparts. Reagent-wise, 
developing a kit for use in analysis of canine, feline or equine samples or samples 
of any other non-human source is mainly a matter of using antibodies raised 
against species-specific antigens. This practice has no bearing on the probability 
of interference since the hosts for antibody production remain the same. Mice, 
sheep, rabbits, goats and chickens are some of the most common hosts for 
immunoassay antibodies in kits developed for use in humans as well as in 
animals.  
However, the immunoassay components only represent one side of the 
equation. For interference to occur, there must be interfering substances present 
in the analyzed samples. Do animals have antibodies against, for instance, 
mouse, sheep, or rabbit IgG? Accumulating evidence is now suggesting that 
these antibodies are not uncommon in the animal population. Anti-mouse and 
anti-rabbit IgG was detected in plasma from cattle (Kashiwazaki & Thammasart, 
1998), and anti-IgG antibodies with fairly broad species reactivity were 
demonstrated in horses (Borromeo et al., 2007). Later, it was found that canine 
plasma contained antibodies reactive with mouse IgG (Solter et al., 2008). The 
publications in this thesis provide additional insight into the prevalence and 
clinical implications of interfering antibodies in dogs (Bergman et al., 2019a; 
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Bergman et al., 2019b; Bergman et al., 2018). Nevertheless, these accounts are 
very slight in numbers compared to the body of work on immunoassay 
interference in people. 
1.4 Interfering antibodies: definitions and nomenclature 
 
The nomenclature on endogenous antibodies that interfere with immunoassays 
is often confusing because terms referring to these antibodies can have different 
meanings in different contexts, and the meanings are user-dependent. There have 
been attempts to categorize the antibodies and to standardize the nomenclature. 
While these attempted categorizations are likely well-intended, they all have 
their imperfections, and because interfering antibodies are very heterogeneous, 
they rarely fall squarely into one category.  
Some researchers have proposed that the commonly used term “heterophilic 
antibodies” should be reserved for antibodies that bind IgG from two or more 
species (Kaplan & Levinson, 1999). However, 20 years later, this use of the term 
has not been adopted by the research community. It seems unrealistic to ask that 
investigators should evaluate each suspected sample for cross-reactivity against 
numerous species before the use of such a widespread term can be justified. It 
has also been recommended that the term “heterophilic antibodies” should 
indicate that the antibodies originate from an unknown exposure to antigen, in 
contrast to rheumatoid factors (which is debatable since rheumatoid factors are 
widely thought to be induced by an unknown antigen), and to HAMAs, which 
are acquired from monoclonal antibody therapy (Bolstad et al., 2013). However, 
anti-mouse antibodies can also be acquired from unknown non-iatrogenic 
exposure to mouse antibodies, making the widely established definition of 
HAMAs imprecise. Furthermore, this definition of heterophilic antibodies does 
not include polyspecific natural antibodies that are present at birth without any 
prior antigen exposure. In practice, the origin of these antibodies, whether there 
was exposure to antigen or not is almost always unknown, and the decreased use 
of murine therapeutic antibodies is making the few cases where a known 
immunogen exists even scarcer. 
The frequent use of the term “heterophilic antibodies”, in the context of 
immunoassay interference, indicates that a sample contains a substance that 
interferes, or is suspected of interfering with, a test without any further 
specification (Bolstad et al., 2013). This broad use of the term works well in 
most scenarios, but if more information about the interfering substance is 
available, the use of a more descriptive term is motivated. Because mouse 
antibodies are not used for therapy in veterinary medicine, there is no principal 
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counterpart to HAMAs in dogs. Herein, “heterophilic antibodies” and “anti-
animal antibodies” are both used as umbrella terms for immunoassay interfering 
antibodies, and where applicable, the term “canine anti-mouse antibodies” is 
used to denote that the interfering antibodies react with mouse antibodies. The 
species reactivity of the antibodies is their most important feature, and in the 
absence of further characterization, it is often one of the few facts about them 
that can be stated with reasonable certainty. However, the term “canine 
heterophilic antibodies” would also suffice to refer to these antibodies. In this 
thesis, “heterophilic antibodies” are not treated as a separate subset of interfering 
antibodies, in line with the widespread notion that all antibodies that cause 
immunoassay interference are heterophilic antibodies. 
1.4.1 Iatrogenic anti-animal antibodies 
Iatrogenic anti-animal antibodies are acquired through medical interventions. 
The classic example is HAMAs in people, resulting from the administration of 
therapeutic monoclonal antibodies.  
The earliest monoclonal immunotherapies relied on mouse antibodies, but 
advances in chemical engineering have made it possible to modify therapeutic 
antibodies to minimize their immunogenicity. One of the major disadvantages 
of injecting a patient with a monoclonal mouse antibody, apart from the risk for 
immunoassay interference, is that the number of effective treatments are very 
few since the patient quickly develops immunity to the drug. Most therapeutic 
antibodies in use today are therefore chimeric or humanized. Chimeric 
antibodies have had their constant region replaced with human amino acid 
sequences, and in humanized antibodies, only the complementarity determining 
regions (CDRs) are of murine origin. Despite these efforts to reduce 
immunogenicity, all current therapeutic antibodies are immunogenic in some 
recipients, and therefore a potential source of immunoassay interference.  
For various reasons, the development of veterinary therapeutic monoclonal 
antibodies has been stagnant in comparison to the avalanche of human 
monoclonal antibodies introduced during the 2010s. As of this writing, there are 
only two veterinary monoclonal antibodies approved, both in the United States, 
for the treatment of cancer in dogs, one for CD20 positive B cell lymphoma and 
one for CD52 positive T cell lymphoma (Klingemann, 2018). The first 
monoclonal antibody approved in the European Union for use in dogs was 
registered in 2017, an IL-13 antagonist for the treatment of atopic dermatitis. All 
of these antibodies have been speciated to limit their immunogenicity 
(Klingemann, 2018; Michels et al., 2016), so it appears that the veterinary 
community is riding the wave of recent advances in antibody engineering. Once 
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canine immunotherapies become more widely available, a sudden outburst of 
immunoassay interference cases, therefore, seems quite unlikely, but some 
precaution is nevertheless advised. 
There is another fairly common clinical treatment in veterinary medicine that 
could be a source of iatrogenic anti-animal antibodies. Dogs envenomated by 
snake bites are sometimes treated with animal antisera. Several commercial 
antivenom treatments for different species of snakes are available for dogs. Most 
of them contain polyclonal horse (Lund et al., 2013) or sheep IgG (KarlsonStiber 
et al., 1997) as whole molecules, Fab-, or F(ab’)2-fragments. Patients treated 
with snake antivenin develop immunity, and the iatrogenic anti-animal 
antibodies could cause immunoassay interference. Sheep antivenin is often 
advocated over horse antivenin due to higher safety, but the risk of immunoassay 
interference should, in theory, be higher after treatment with sheep antivenin due 
to the more frequent use of sheep IgG in immunoassays. 
1.4.2 Non-iatrogenic anti-animal antibodies 
Most commonly, the anti-animal antibodies that interfere with immunoassays 
are not traceable to a medical treatment or a known exposure to an immunogen. 
It is widely assumed that the bulk of interfering antibodies result from 
commonplace activities, like pet-keeping, vaccinations and food consumption 
(Ismail, 2009). However, causality is rarely or never proved, and correlational 
studies investigating risk factors are rare, although there are exceptions 
(Mohammadi & Bozorgi, 2019). It is also commonly assumed that these 
antibodies were acquired from exposure, although this is not a prerequisite. 
There are also natural antibodies, present before birth and exposure to antigen, 
which provide a rudimentary line of defence against infections by initiating weak 
interactions with a broad range of antigens. These antibodies are polyspecific 
antibodies of the IgM isotype and appear to recognize, for example, 
carbohydrates on the cell surface of bacteria. Antibodies with these 
characteristics can cause immunoassay interference (Covinsky et al., 2000). 
There is experimental evidence showing that the binding between antibody and 
antigen is more flexible than implied by the traditional “lock and key”-principle 
for antibody-antigen interactions (James et al., 2003; Kramer et al., 1997) and 
that antibodies can change their conformation to accommodate numerous 
antigens. These findings could explain how polyspecific antibodies in 
individuals that have never been exposed to animal IgG are capable of interfering 
with immunoassay antibodies.  
If exposure is a source of anti-animal antibodies, which seems plausible, the 
question is which route of exposure that most likely leads to an immune 
20 
 
response. Because antigen-presenting cells are abundant in subcutaneous tissues, 
exposed wounds would appear to be a candidate exposure route. However, in a 
study investigating laboratory workers that were habitually exposed to mice, the 
frequency of mouse bites was not a risk factor for the development of anti-mouse 
antibodies (Mohammadi & Bozorgi, 2019). The amount of antigen transferred 
through bites may be insufficient to induce antibody formation. Immunization 
via the gut is another possible route for the acquisition of anti-animal antibodies, 
and cow’s milk, especially when unpasteurized, contains relatively high levels 
of bovine immunoglobulin (Hurley & Theil, 2011) and could be a means of 
immunization in people (Hunter & Budd, 1980). It is not common practice to 
feed dogs with milk, but in recent years, raw feeding diets for dogs have 
increased in popularity. These diets consist of uncooked edible bones and organs 
that might provide the dogs with a sufficient dose of animal immunoglobulin to 
form anti-animal antibodies. It is also possible that the hunting and eating of wild 
animals is a source of anti-animal antibodies in dogs and cats. However, this 
proposed immunization route is inconsistent with the concept of oral tolerance 
to food protein (Pabst & Mowat, 2012). 
1.4.3 Rheumatoid factors 
Erik Waaler described rheumatoid factors in 1940 (Waaler, 1940). Historically, 
they were defined as IgM autoantibodies that bind to the Fc-region of IgG 
(Figure 2), but numerous variants exist, including IgA/IgG to IgM, and IgG/IgM 
to IgA. Rheumatoid factors against its own Ig isotype are also found (IgA to IgA, 
IgG to IgG and IgM to IgM), but these require relatively sophisticated detection 
methods and are less well studied. Rheumatoid factors in people are linked to 
numerous conditions, including autoimmune diseases like rheumatoid arthritis 
and Sjögren’s syndrome, as well as viral, bacterial and parasitic infections 
(Newkirk, 2002). Rheumatoid factors may be present in both chronic and acute 
conditions. In infections, the response is typically transient. It has been proposed 
that the rheumatoid factor acts as a “housecleaner” in infectious disease by 
contributing to the formation of immune complexes that are cleared from 
circulation by the mononuclear phagocyte system (Hogben & Devey, 1986; Van 
Snick et al., 1978). It is also possible that B cells expressing rheumatoid factors 
on their surface contribute to the immune response by presenting foreign antigen 
to T cells (Roosnek & Lanzavecchia, 1991).  
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Figure 2. Schematic diagram of the IgG structure. Legend: 1. Fab region, 2. Fc region, 3. Heavy 
chain (from top to bottom consisting of variable heavy (VH) and constant heavy (CH1), hinge, CH2 
and CH3 domains), 4. Light chain (from top to bottom consisting of VL and CL domains), 5. 
Antigen-binding site, 6. Hinge region. By Y_tambe / CC BY-SA 
(https://upload.wikimedia.org/wikipedia/commons/1/19/Immunoglobulin_basic_unit.svg) 
Testing for rheumatoid factors can be useful in the clinical diagnosis of 
rheumatoid arthritis in people. Rheumatoid factors are also of technical concern 
in immunological assays due to their ability to bind IgG. Knowledge about the 
characteristics and binding properties of rheumatoid factors is required in order 
to configure immunoassays in such a way that interference is limited. The most 
common binding site for rheumatoid factors is the CH2-CH3 groove or the CH3-
CH3 groove on the Fc region of IgG (Duquerroy et al., 2007; Artandi et al., 
1992). There are also several species-specific binding sites on the Fc region. The 
entire Fc region belongs to the constant region of IgG and is therefore 
independent of the specificity of the antibody. This region of IgG has been well 
conserved throughout evolution. Interspecies homology in this region enables 
rheumatoid factors to bind IgG from several different species and to interfere 
with immunoassays by cross-reacting with, e.g. mouse, rabbit, and sheep IgG. 
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The homology decreases as the phylogenetic distance to the target IgG increases. 
This principle explains why chicken IgY is a viable option for avoiding 
interference from rheumatoid factors in mammals – the structural difference 
between mammalian and avian immunoglobulin is unbridgeable for the 
rheumatoid factors (Larsson & Sjoquist, 1990). 
Research activity on canine rheumatoid factors peaked in the late 1980s-early 
1990s (Chabanne et al., 1993; Carter et al., 1989). It was then found that IgA 
and IgM rheumatoid factors are detectable in canine sera and that they 
occasionally may be useful in the diagnosis of rheumatoid arthritis. Most of these 
studies were carried out using older detection methods such as the Rose-Waaler 
test or the latex fixation test, which are mainly suitable for detecting rheumatoid 
factors of the IgM isotype. In human medicine, nephelometry is most commonly 
used for the detection of rheumatoid factors. The Rose-Waaler test remains the 
gold standard for detecting rheumatoid factors in animals, but ELISA (enzyme-
linked immunosorbent assay) testing is considered an acceptable alternative, 
which also has the advantage of being able to detect rheumatoid factors of all 
isotypes (Andrysikova et al., 2009). However, available tests are insensitive, and 
the diagnostic value is unclear. The interest in canine rheumatoid factors has 
declined since the 1990s, but their existence still represents a potential risk for 
interference in immunoassay testing for other analytes.  
1.4.4 Anti-Fab/F(ab’)2-autoantibodies 
Rheumatoid factors are commonly discussed in connection with immunoassay 
interference because they bind to conserved regions on the Fc domain of IgG. 
What is sometimes overlooked in this discourse is that the constant region 
extends well into the fragment antigen-binding (Fab) region of IgG, and thus 
autoantibodies against this region are capable of causing interference via the 
same mechanism as rheumatoid factors. These autoantibodies can be divided 
into different subsets depending on their exact specificity, but they are often 
called anti-Fab or anti-F(ab’)2-autoantibodies.  
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Figure 3. IgG molecule cleaved with papain to yield Fab-fragments. The Fab fragment retains the 
upper IgG hinge region. By Je at uwo on en.wikipedia derivative work: Vezixig / Public domain 
(https://commons.wikimedia.org/wiki/File:2fab_fc.svg)  
In vitro, Fab-fragments are produced by cleavage of whole IgG using papain. In 
older literature, anti-Fab-autoantibodies were called papain agglutinators, 
denoting their ability to agglutinate erythrocytes covered with Fab-fragments 
obtained by papain cleavage (Kormeier et al., 1968). Likewise, anti-F(ab’)2-
autoantibodies were called pepsin agglutinators, as pepsin is used to produce 
F(ab’)2-fragments in vitro (Osterland et al., 1963). If the autoantibodies bind to 
the constant heavy chain domain (CH1) or the light chain domain (CL) on the 
Fab region of IgG, the designations anti-Fab and anti-F(ab’)2-autoantibodies are 
interchangeable. However, if they bind to the hinge region, these designations 
tend to become mutually exclusive. When Fab- and F(ab’)2-fragments are 
cleaved with papain or pepsin, cryptic epitopes (epitopes that are not exposed on 
the intact IgG molecule) become revealed in the upper or lower hinge region. 
Papain cleaves IgG in the upper hinge region (Figure 3). Autoantibodies 
targeting cryptic epitopes in the upper hinge will, therefore, recognize Fab-
fragments, but not F(ab’)2-fragments, nor intact IgG. Pepsin cleaves IgG in the 
lower hinge region (Figure 4), so likewise, autoantibodies targeting cryptic 
epitopes in the lower hinge region will recognize F(ab’)2-fragments, but not Fab-
fragments, nor intact IgG. Autoantibodies with these specificities are often 
called anti-hinge-autoantibodies to distinguish them from autoantibodies against 
heavy or light chain domains. Anti-hinge-autoantibodies to the lower hinge 
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region are more common or at least more often studied than anti-hinge-
autoantibodies to the upper hinge region, although both types have been 
described (Elagib et al., 2001). It should be emphasized that in many studies, 
exact characterization of the binding sites was not performed, so the designations 
anti-Fab or anti-F(ab’)2-autoantibodies are principally used as umbrella terms to 
indicate that their binding could be directed to any part of the Fab region of IgG. 
Technically, anti-idiotypic antibodies are also anti-Fab and anti-F(ab’)2-
autoantibodies, but as such, they represent a particular subset of antibodies, and 
they are reviewed separately. 
 
 
 
Figure 4. IgG molecule cleaved with pepsin to yield F(ab’)2-fragments. The F(ab’)2-fragment 
retains the entire IgG hinge region. By Je at uwo on en.wikipedia / Public domain 
(https://commons.wikimedia.org/wiki/File:F_ab2_pFc.png) 
Initial studies revealed that anti-Fab and anti-F(ab’)2-autoantibodies were nearly 
ubiquitous in the human population (Waller et al., 1971) and that it was not 
uncommon for these antibodies to recognize cryptic epitopes exposed by pepsin 
or papain, predominantly in the lower hinge region of IgG. However, neither 
pepsin nor papain is present nor biologically active under normal physiological 
conditions in vivo. Efforts were therefore made to identify other proteolytic 
enzymes that are capable of cleaving IgG in vivo. It was found that several 
enzymes can digest IgG in vivo and that many of these are disease-associated. 
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Notably, several tumour-associated matrix metalloproteinases (MMPs) cleave 
human IgG in the lower hinge region, proximal to or at the same site as pepsin 
(Brezski & Jordan, 2010). The bacterial enzymes glutamyl endopeptidase 
(GluV8) (Ryan et al., 2008) and IdeS (von Pawel-Rammingen et al., 2002), as 
well as cathepsin G, were also found to cleave IgG in this region. In addition, 
plasmin and human neutrophil elastase (HNE) cleave IgG in the upper hinge 
region (Brezski et al., 2008). 
Anti-F(ab’)2-autoantibodies are rarely considered as sources of immunoassay 
interference, despite the significant homology between CH1 and CL domains 
from different species. Use of F(ab’)2-fragments instead of whole IgG molecules 
in immunoassays has even been endorsed as a prophylactic measure against 
interference (Bolstad et al., 2012). This view has been challenged by other 
researchers claiming that most interfering antibodies target F(ab’)2-fragments 
(Levinson & Miller, 2002; Hennig et al., 2000). In these cases, most of the 
discussion is focused on anti-idiotypic antibodies that bind to the variable region 
of animal IgG.  
1.4.5 Anti-idiotypic antibodies 
The distinction between “antibody” and “antigen” does not acknowledge a 
complicating factor: that antibodies themselves are antigenic, and can act as 
antigens to other antibodies. The variable region of all antibodies contain an 
antigen to which other antibodies can bind. This antigen is called the idiotype of 
the antibody, and antibodies that bind to the idiotype are called anti-idiotypic 
antibodies. Because the anti-idiotypic antibodies also contain an idiotype of their 
own, they can be bound by anti-anti-idiotypic antibodies, in a potentially endless 
cascade of antibody generations. Niels Jerne envisioned an “immune network” 
to explain this peculiar feature of humoral immunology (Jerne, 1974). Much 
simplified, through upregulation and downregulation of different generations of 
anti-idiotypic antibodies, the immune network acts to keep the immune system 
in a state of equilibrium when challenged with an antigen. These cascades of 
antibody generations might, for example, be a way for the immune system to 
maintain the antibody response to a specific antigen over a prolonged period. 
Few immunologists subscribe to the immune network theory today, but the 
existence of anti-idiotypic antibodies is not in question. Although direct 
evidence for their role in immunoassay interference is lacking, they could 
account for several observations that are often made in connection to 
interference. First, the addition of high concentrations of non-immune IgG may 
be insufficient to eliminate the interference. If antibodies targeting a specific 
idiotype happen to be abundant in an individual sample, a serum pool of non-
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immune IgG might not contain sufficient amounts of antibodies against this 
specific idiotype to block the interference. Second, a sample may cause 
interference in one immunoassay but not in another immunoassay for another 
analyte, despite the assays being very similar in terms of antibody reagents and 
species of IgG used (Levinson & Miller, 2002). This finding is sometimes 
attributed to differences in the contents of the blocking buffers, but these 
conclusions are usually speculative at best since the contents of these buffers are 
rarely or never disclosed by the manufacturer. Third, the use of Fab- or F(ab’)2-
fragments instead of whole IgG sometimes fails to eliminate the interferences. 
This observation is consistent with the presence of anti-idiotypic antibodies, 
although the binding could also be towards any other part of the Fab region. 
1.4.6 Other interfering antibodies 
Antibodies do not have to bind IgG to cause immunoassay interference; there 
are numerous types of antibodies with affinities for test analytes and reagents 
that are known to cause false-positive or false-negative test results. Although 
these various types of antibodies are not the main focus of this thesis, they serve 
as relevant differential diagnoses to anti-IgG interference in the medical 
conditions and detection methodologies that they are associated with, and they 
are therefore reviewed here. 
Autoanalyte antibodies  
In diseases with autoimmune etiologies, autoanalyte antibodies may be present 
in patient sera. Some examples are anti-thyroid hormones in Hashimoto’s 
thyroiditis (Despres & Grant, 1998) and anti-insulin antibodies in insulin 
autoimmune syndrome (Casesnoves et al., 1998). Autoantibodies interfering 
with immunoassays are also found in healthy individuals where a connection to 
autoimmunity has not been found (Eriksson et al., 2005). Anti-insulin antibodies 
have been detected in healthy cats and were found to affect serum insulin 
measurements (Nishii et al., 2010). The factors determining the nature of the 
interference (false increase or false decrease) are complex and depend on the 
detection method. Although autoanalyte antibodies potentially can affect all 
immunoassays, they should, in particular, be considered as sources of 
interference in immunoassays where anti-IgG-antibodies are less likely to affect 
the results, i.e. competitive assays (Miller, 2004). 
In dogs, hypothyroidism often concurs with autoimmune thyroiditis (AIT), 
and dogs presenting with AIT may have autoantibodies against thyroglobulin 
(TgAA) that cross-react with triiodothyronine (T3) and thyroxine (T4). Unless 
non-immunological detection methods are used, T3 and T4 can only be measured 
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by competitive immunoassays due to their low molecular weight, and in this 
format, autoanalyte antibodies can impact the measurements by reacting with 
labelled analytes. The net result in most thyroid hormone assays is a falsely 
increased measurement. In a large cohort study, it was found that autoantibodies 
falsely increased 5.7% of free T3 measurements and 1.7% of free T4 
measurements in canine samples (Nachreiner et al., 2002). The issues of 
autoanalyte interference in immunological assays for free T3 and T4 have been 
considered so unacceptable that more expensive and laborious methods like 
equilibrium dialysis are being recommended for measurement of thyroid 
hormones in animals (Ferguson, 2007). 
Anti-streptavidin antibodies 
Immunoassays often utilize the biotin-streptavidin system for detection. 
Biotinylated antibodies or antigen bind to enzyme-conjugated streptavidin 
through one of the strongest non-covalent interactions observed in nature. One 
of the advantages of using enzyme-conjugated streptavidin is that it can function 
as a generic linker to any biotinylated antibody or antigen, eliminating the need 
for individual enzyme-conjugation of different antibodies and antigen. However, 
there are at least two mechanisms of interference specific to immunoassays 
employing this system. One is interference from biotin, recently described as an 
“emerging interferent” (Luong et al., 2019) in immunoassays. In this case, the 
interference is mediated by high sample concentrations of biotin rather than by 
antibodies – biotin is a small, poorly immunogenic molecule that does not induce 
antibody formation. The other mechanism is interference from anti-streptavidin 
antibodies (Wouters et al., 2019; Peltier et al., 2016; Rulander et al., 2013), 
which are receiving increased recognition as interfering agents. These antibodies 
might be acquired via intake of protein supplements (Harsch et al., 2017). In 
electrochemiluminescent assays, ruthenium is used to label antibodies. 
Interference from anti-ruthenium antibodies has also been described (Buijs et 
al., 2011). To date, there have not been any reports on interference from 
antibodies against antibody labels in animals. 
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The overarching aim of this thesis was to investigate the prevalence, clinical 
impact, molecular characteristics and origin of heterophilic antibodies in dogs. 
The specific aims were to: 
 
 Set up a species-independent interference assay for detecting anti-mouse 
antibodies, and to use it to determine the prevalence of anti-mouse antibodies 
in a cross-section of dog and cat patients (paper I) 
 Determine if canine anti-mouse antibodies are a source of clinically relevant 
interference in a commercial immunoassay (paper II) 
 Evaluate antibody precipitation as a method for detecting interference in a 
variety of hormone immunoassays used in veterinary medicine (paper II) 
 Determine if there is a breed variation in the prevalence of canine anti-mouse 
antibodies (paper III) 
 Characterize the fragment-specific binding properties, species cross-
reactivity and immunoglobulin isotypes of canine anti-mouse antibodies 
(paper III) 
 Follow up dogs with anti-mouse antibodies prospectively to determine the 
connection of the antbodies to disease, as well as their duration in serum over 
two years (manuscript IV) 
 Test if autoantibodies to the Fc- and F(ab’)2-fragments of IgG cross-react 
with mouse IgG and if the binding is derivable to cryptic epitopes in the hinge 
region of IgG (manuscript IV) 
 
  
2 Aims of the thesis 
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The materials and methods are presented here in a condensed version. For more 
detailed descriptions, see each individual paper. 
3.1 Screening for anti-mouse antibodies 
 
For paper I, we collected 369 samples from 320 dogs and 263 samples from 218 
cats and screened them in an ELISA for anti-mouse antibodies. Multiple dog and 
cat breeds of both sexes and with varying ages were represented. The samples 
were collected from the routine diagnostic analysis at the University Animal 
Hospital, so most of the animals had some clinical diagnosis or clinical signs of 
disease. Except for the exclusion of samples with inadequate volumes and 
samples with hemolysis, bilirubinemia or lipemia, there were no selection 
criteria. 
The screening assay was an immunometric assay using mouse IgG for 
capture and detection. The assay was developed in-house with commercial 
reagents. We used a 3-step format, with no co-incubation of sample and antibody 
and washed the wells between each incubation step. The detection antibody was 
conjugated directly to HRP (horseradish peroxidase). There was no calibration 
of the unknown samples, but we generated a standard curve using chicken anti-
mouse IgG for evaluating the quality of each run and also as a practical means 
of obtaining a cut-off (the 7th point of the standard curve). Results for unknown 
samples were presented on a relative scale where the optical density (OD) of the 
sample was divided by the OD of the cut-off point. The screened patients were 
categorized by age, sex, breed, neutering status and clinical disease groups, and 
statistical analysis was performed to assess differences between patients positive 
and negative for anti-mouse antibodies within each of these categories. Risk 
3 Materials and methods 
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factors were assessed for both dogs and cats. The prevalence of anti-mouse 
antibodies was also compared between dogs and cats. Samples positive for anti-
mouse antibodies were tested for cross-reactivity to chicken IgY by substituting 
the mouse IgG capture antibody for chicken IgY.  
3.2 Interference in commercial hormone immunoassays 
for dogs 
 
The sample material for the study contained in paper II consisted of serum 
testing positive for interference in paper I (28 sera from 27 dogs). We decided 
to only follow through with the positive dog samples. Serum was collected from 
25 healthy dogs without anti-mouse antibodies to establish a control group. We 
selected four immunoassays representing a variety of formats (immunometric 
and competitive) and antibody reagents: mouse, sheep and rabbit IgG. The 
included assays were AMH, canine TSH, canine TT4 and progesterone. They 
were selected and prioritized based on the importance of an individual 
measurement for the clinical diagnosis and the frequency of their use in 
veterinary patient care. 
For investigating interference in the AMH assay, we matched the result 
against the neutering status of the animal. If a neutered dog had detectable AMH 
concentrations, we blocked the serum with different concentrations of mouse 
IgG, native and heat-treated and compared the measurements before and after 
treatment. We also treated the sample with 24% PEG to precipitate the 
immunoglobulins and evaluated the obtained result for discrepancy against the 
original result. This was the only sample treatment performed in the rest of the 
assays (canine TSH, canine TT4 and progesterone). Measurements that differed 
by more than four standard deviations (SD) from the intra-assay CV were 
considered discrepant. By default, CVs are calculated based on one SD, which 
amounts to a 68% probability that two repeat measurements of a sample deviate 
within the confines of the assay CV. If 4 SDs instead are used to calculate the 
CV, the probability increases to 99.99%. Given these conditions, there is only a 
0.01% probability of obtaining a discrepancy between two measurements for 
any other reason than the PEG treatment. The number of discrepancies for 
samples with anti-mouse antibodies was then compared to the number of 
discrepancies for samples without anti-mouse antibodies by using a T-test for 
two proportions. 
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3.3 Breed predisposition and characterization of canine 
anti-mouse antibodies 
 
Serum was obtained from a mixed population of healthy dogs and dogs with 
clinical diagnosis, in total, 51 Bernese mountain dogs and 53 Labrador 
retrievers. Both excess serum from clinical cases and dogs belonging to private 
volunteering owners was used. The samples were screened with a method 
similar to the one in paper I, but here, we tested each sample for reactivity to 
whole molecules, Fc- fragments and F(ab’)2-fragments of mouse IgG. We then 
defined a positive sample for anti-mouse antibodies as one testing positive in at 
least one of these assays. The cut-off for each assay was set to the assay LoD 
(limit of detection) + 4 SD. The number of positive samples for Bernese 
mountain dogs and Labrador retrievers were statistically compared with a paired 
T-test. 
Fragment-specific reactivity was obtained in the breed comparison. Samples 
testing positive for anti-mouse antibodies were further evaluated for cross-
reactivity by substituting the capture antibody for different species of IgG (goat, 
rabbit, sheep and chicken IgY). Isotyping of positive samples was performed by 
coating the plate with mouse IgG, and detecting with goat anti-dog antibodies, 
isotype-specific for IgA, IgG and IgM. 
3.4 Clinical significance, duration and possible origin of 
canine anti-IgG antibodies 
 
A questionnaire was designed and distributed to private owners of dogs 
participating in the paper III study. An online survey provider hosted the 
questionnaire, and a link was distributed to owners that had supplied an e-mail 
address. Owners without e-mail contact information were surveyed via 
telephone. The survey was open for completion for six weeks. The questionnaire 
queried dog owners on any disease investigations undertaken at veterinary 
clinics during the years 2017 and 2019, and they were asked to specify which 
type or types of disease within the categories skin disease, kidney disease, 
gastrointestinal disease, nervous disease, tumour disease, orthopaedic disease, 
cardiac disease and other disease. Further questions were asked about any 
ongoing pharmacological treatments and observed contact with mice or other 
rodents. It was possible to specify the answer in free-text boxes for questions 
regarding clinical diagnoses or clinical signs of disease. At the end of the 
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questionnaire, it was possible to volunteer dogs for follow-up collection of 
serum samples. 
Statistical testing was performed to determine if the presence of canine anti-
mouse antibodies is a risk factor for the development of disease in general, as 
well as within specific disease categories. Follow-up samples were tested for the 
presence of anti-mouse antibodies with the method described in paper III. In 
addition, 57 serum samples collected in 2017 and 2019 were analyzed for 
autoantibodies to IgG (anti-Fab and anti-F(ab’)2-autoantibodies). Plates were 
coated with Fab- or F(ab’)2-fragments of dog IgG. Autoantibodies were detected 
using Fc-specific goat anti-dog IgG. The levels of autoantibodies were compared 
between anti-mouse positive and anti-mouse negative cohorts. Levels of anti-
Fab and anti-F(ab’)2-autoantibodies were tested for statistical relationships with 
the health status, sex, age and breed of the dogs. Samples with anti-F(ab’)2-
autoantibodies were blocked with mouse IgG and mouse F(ab’)2 to assess cross-
reactivity. 
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The main results from paper I-IV are summarized here. More details are found 
in the respective papers. 
4.1 Prevalence of anti-mouse antibodies in a cross-
section of dog and cat patients and interference 
elimination with chicken IgY as capture antibody 
(paper I) 
 
In total, 9% of tested dogs (28/320) and 5% of cats (10/218) were positive for 
interference. The relative OD for positive samples ranged between 1.005 and 
2.019 for dogs and between 1.049 and 2.081 for cats (Figure 5). The median age 
of interference-positive dogs (dogs with anti-mouse antibodies) was seven years. 
There were 11 intact males, three neutered males, ten intact females, and four 
spayed females of 24 different breeds. The median age of interference-positive 
cats was 8.5 years. There were six neutered males, one intact female, and three 
spayed females of 5 different breeds. Age, sex, breed, neutering status and 
diagnostic category comparisons between interference-positive and 
interference-negative dogs and cats were not statistically significant. 
 
4 Results 
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Figure 5. Dog (n = 369) and cat (n = 263) samples were screened with a 3-step immunometric 
ELISA using nonimmunized mouse IgG as the capture antibody. An HRP-conjugated monoclonal 
mouse IgG1k anti-CEA antibody was used as the detection antibody. The dashed horizontal line 
indicates the cutoff level. The results are presented on a relative scale and calculated according to 
the formula: (mean sample OD)/(mean cutoff OD). There was no significant difference in the 
prevalence of interference between dogs and cats (P = .06). From Paper I (Bergman et al., 2018). 
 
Coating the microtiter wells with chicken IgY reduced the signal significantly 
(P < .001) as compared to wells coated with mouse IgG. All 19 assayed samples 
were negative when chicken IgY was used as the capture antibody. Five samples 
previously determined to be positive tested negative in this experiment. (Figure 
6). 
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Figure 6. Reactivity against nonimmunized mouse IgG and chicken IgY using an HRP-conjugated 
mouse IgG1k anti-CEA antibody for detection. The dashed horizontal line indicates the positive 
cutoff level. The results are presented as (mean sample OD)/(mean cutoff OD) 
 
4.2 Effects of interference elimination treatments on 
samples with falsely elevated AMH results (paper II) 
 
Samples from two of seven neutered dogs with anti-mouse antibodies yielded 
detectable AMH concentrations. They corresponded to the strongest reactivity 
to anti-mouse IgG of all screened samples in study 1. 
The initial AMH measurement for serum 1 was 14.49 pmol/L. Heat‐
aggregated MAK33 (0.5 mg/mL) yielded a decreased by 22% (to 11.28 pmol/L), 
and 1.0 mg/mL of heat‐aggregated MAK33 yielded a decreased by 57% (to 6.28 
pmol/L) (Figure 7). Combined treatment with 0.5 mg/mL heat‐aggregated 
MAK33 + I5381 decreased the result by 62% (to 5.50 pmol/L).  
The initial measurement of AMH on serum 2 was 5.71 pmol/L. The same 
interference testing was performed as for serum 1. Treatment with 1.0 mg/mL 
heat-treated MAK33 and 0.5 mg/mL MAK33 + 0.5 mg/mL I5381 both yielded 
undetectable AMH concentrations. The AMH concentrations for both sera were 
below the detection limit after treatment with PEG. 
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Figure 7. Effects of polyethylene glycol (PEG) treatment and antibody blocking on samples with 
erroneous anti‐Müllerian hormone (AMH) results. For blocking, different concentrations of two 
mouse antibodies (MAK33 and I5381) were used. The antibodies were also used in combination 
with 0.5 mg/mL of each. From paper II (Bergman et al., 2019a) 
4.3 Effects of antibody precipitation on hormone 
measurements in samples with and without anti-
mouse antibodies (paper II) 
 
The effects of the PEG treatments are summarized (Table 1). In total, 127 paired 
analyses were performed. Out of these analyses, 100 (79%) returned informative 
results. Non-informative results included results that were outside of the assay 
range before PEG treatment or that returned an error code after PEG treatment. 
When the result after PEG treatment was below the assay range, the lowest value 
was divided by two for statistical calculations. 
There was a significant difference in the probability of getting a discrepant 
result post-PEG treatment depending on whether AMH, TSH, TT4, or 
progesterone was analyzed. This difference was significant for samples with 
anti-mouse IgG, without anti‐mouse IgG, as well as for all samples (P < 0.001 
in all three cases). Presence or absence of anti‐mouse antibodies did not affect 
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the probability of getting a discrepant result for any of the assays, except the 
canine TT4 assay (P = 0.04). 
Five of the 29 patient samples (17%) with anti‐mouse antibodies did not 
cause discrepant results in any of the tested immunoassays. Conversely, 
discrepant results were found in at least one of the immunoassays for all 25 
serum samples without anti‐mouse antibodies. 
 
Table 1. A summary of the polyethylene glycol (PEG) effects. The effects on hormone measurements 
after PEG treatment for samples with (Anti-mouse+) and without (Anti-mouse-) anti‐mouse 
antibodies. From paper II (Bergman et al., 2019a) 
 Number of discrepancies Measurement decrease 
 Anti-mouse+ Anti-mouse- Anti-mouse+ Anti-mouse- 
AMH 
TSH 
14/14(100%) 
5/10 (50%) 
17/17 (100%) 
8/10 (80%) 
75% 
26% 
68% 
38% 
TT4 
Progesterone 
6/14 (43%) 
0/6 
15/18 (83%) 
1/11 (9%) 
23% 
0 
38% 
0 
Overall 25/44 (57%) 41/56 (73%) 29% 41% 
 
4.4 Breed predisposition and characterization of canine 
anti-mouse antibodies (paper III) 
4.4.1 Breed predisposition 
In total, 110 samples from 104 dogs, 51 Bernese mountain dogs (two with two 
samples) and 53 Labrador retrievers (four with two samples) were included in 
the screening for breed differences. The Bernese mountain dog cohort consisted 
of 25 intact females, eight neutered females, 11 intact males and seven neutered 
males. There were fifteen Bernese mountain dogs (29%) with clinical signs of 
disease or disease diagnosis at the time of sampling. The median age was three 
years. The Labrador retriever cohort consisted of 14 intact females, eight 
neutered females, 28 intact males and three neutered males. Twenty-nine of the 
Labrador retrievers (55%) were diagnosed with disease or had clinical signs of 
disease. The median age was four years. The incidence of clinical disease or 
clinical signs of disease was increased in Labrador retrievers (P< 0.01) and the 
proportion of intact females was greater in Bernese mountain dogs (P=0.02). 
Fourteen samples from 12 of the 104 dogs (12%) tested positive for anti-
mouse antibodies in the screening. The positive cohort consisted of ten of 51 
screened Bernese mountain dogs (20%), and 2 of 53 screened Labrador 
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retrievers (4%). Two dogs, one Bernese mountain dog and one Labrador 
retriever submitted two positive samples. There was a significant difference in 
the prevalence of anti-mouse antibodies between the breeds (P=0.03). The 
median age of dogs positive for anti-mouse antibodies was 3.5 years. In the 
positive cohort, there were three each of females, males, neutered females and 
neutered males. There were six dogs with a diagnosed disease or clinical signs 
of disease at the time of sampling.  
4.4.2 Characterization of anti-mouse antibodies 
Out of the 14 positive samples from 12 dogs, reactivity to whole IgG and F(ab’)2-
fragments was found in five samples from five dogs (42% of the dogs), reactivity 
to whole IgG only in three samples from three dogs (25%), reactivity to whole 
IgG and Fc-fragments in three samples from two dogs (17%) and reactivity to 
Fc-fragments only in three samples from two dogs (17%). None of the samples 
reacted with both Fc- and F(ab’)2-fragments.  
Following testing for cross-reactivity to IgG from different species, reactivity 
to IgG from multiple species was found in two of the 14 positive samples from 
12 dogs (17%). Cross-reactivity to goat IgG was found in two samples from two 
dogs (17%) and to sheep IgG in one sample from one dog (8%). Cross-reactivity 
to goat IgG and sheep IgG was found in one sample (8%). 
Antibody isotyping revealed that two of the eight isotyped samples (25%) 
were positive for IgG only, three (37%) for IgM only, and two (25%) for IgA, 
IgG and IgM. One sample (12%) was negative for all isotypes. The 
characterization of anti-mouse antibodies is summarized (Table 2). 
 
Table 2. Summary of the antibody characterization performed in this study. Isotyping was not 
performed. From paper III (Bergman et al., 2019b) 
Breed Age  Sex Clinical 
signs/diagnosis 
Anti-mouse 
reactivity 
Cross-
reactivity 
Isotype 
BMD 3 MN - Whole IgG, F(ab’)2  IgA, 
IgG, 
IgM 
BMD 3 FN - Whole IgG  IgG 
BMD 1 F - Whole IgG, F(ab’)2  IgM 
BMD 1 F - Whole IgG, F(ab’)2 Goat N/A 
LR 8 M - Whole IgG, F(ab’)2 -* N/A 
BMD 4 M - Whole IgG  IgM 
BMD 5 FN Lipoma Whole IgG, F(ab’)2  IgA, 
IgG, 
IgM 
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Breed Age  Sex Clinical 
signs/diagnosis 
Anti-mouse 
reactivity 
Cross-
reactivity 
Isotype 
BMD*** 8 MN Protein-losing 
enteropathy 
Whole IgG, Fc  IgG 
BMD 10 FN Anterior cruciate 
ligament injury 
Whole IgG Goat, sheep N/A 
BMD 1 F Gastric dilatation 
volvulus 
Whole IgG, Fc  - 
BMD 6 M Mast cell tumour Fc  IgM 
LR*** 3 MN Polyuria/polydipsia Fc -** N/A 
 
* Not tested for reactivity to chicken IgY. **Not tested for reactivity to rabbit IgG or chicken 
IgY. ***Two samples from this dog were analyzed. 
 
4.5 Clinical significance, duration and possible origin of 
canine anti-IgG antibodies (manuscript IV) 
4.5.1 Clinical significance of anti-mouse antibodies 
Out of the 107 dogs participating in the previous study in 2017, 95 dogs were 
followed up by contacting 73 owners via telephone or e-mail. The survey 
responses were inferred from available medical records for seven euthanized 
dogs. When all completed questionnaires and inferred responses from medical 
records were counted, the response rate was 73% (75/102). During the follow-
up period, seventeen dogs (22.7%) had been euthanized, 11 Bernese mountain 
dogs (median age: eight years) and 6 Labrador retrievers (median age: nine 
years). One of these dogs was positive for anti-mouse antibodies in the initial 
testing in 2017. 
In the two years between 2017 and 2019, 61% of the dogs had been 
investigated for disease. Out of these dogs, 24% were included in multiple 
disease categories. The most common disease category for Bernese mountain 
dogs was neoplastic disease (23%) and for Labrador retrievers orthopaedic 
disease (26%). The proportions of positive and negative dogs within the different 
disease categories are displayed (Figure 8). 
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Figure 8. Allocation of diagnoses for different disease categories, including healthy dogs. Stacked 
bars are separated into two groups based on dogs testing positive or negative for heterophilic 
antibodies in 2017. 
 
There was no overall significant difference in disease between the positive and 
the negative cohort (P=0.5); neither was there a significant difference within any 
of the specific disease categories. 
4.5.2 Exposure to mice as a risk factor for anti-mouse antibodies 
Owners reported no observed contact with mice for nine out of ten dogs that 
tested positive for heterophilic antibodies against mouse IgG in 2017. There was 
no available information on mouse contact for the tenth dog, which had been 
euthanized during the follow-up period. There was no observed contact with 
mice for three dogs testing positive for heterophilic antibodies against mouse 
IgG in 2019 only. Out of the dogs testing negative for anti-mouse antibodies in 
2017, contact with mice was reported for 11% of the dogs (7/65). 
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4.5.3 Serum duration of anti-mouse antibodies 
Ten out of 12 dogs that tested positive in 2017 participated in the study, and 
seven of them contributed new samples. Six out of these seven dogs remained 
positive at the follow-up sampling. Three additional dogs that were negative in 
2017 were positive in 2019. The age, breed, sex, clinical signs or diagnosis and 
antibody reactivities for these dogs are presented in Table 3. None of the Fc-
reactive samples had shifted to become F(ab’)2-reactive or vice versa. 
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4.5.4 Clinical significance of anti-Fab/F(ab’)2-autoantibodies 
There was no significant statistical relationship between levels of anti-F(ab’)2-
autoantibodies and health status, cancer diagnosis, breed or sex. The correlation 
between age and levels of anti-F(ab’)2-autoantibodies was negligible. 
For anti-Fab-autoantibodies, levels were higher in dogs with a diagnosis or 
clinical signs of disease (P=0.03), but there was no significant statistical 
relationship between levels of anti-Fab-autoantibodies and cancer diagnosis, 
breed, nor sex. The correlation between age and levels of anti-Fab-
autoantibodies was negligible. 
The reactivity to F(ab’)2-fragments was significantly higher than the 
reactivity to Fab-fragments (Figure 9, P<0.01). There was a low positive 
correlation between the levels of anti-Fab-autoantibodies and anti-F(ab’)2-
autoantibodies (rs = 0.39, P<0.01).  
 
 
Figure 9. OD values for IgG anti-Fab and anti-F(ab’)2-autoantibodies in 57 dog samples. IgG anti-
F(ab’)2-autoantibody levels were significantly higher than anti-Fab-autoantibody levels (P < 0.01). 
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4.5.5 Relationship between canine anti-IgG autoantibodies and anti-
mouse antibodies 
We blocked 35 samples analyzed for anti-F(ab’)2-autoantibodies with 0.5 
mg/mL dog F(ab’)2, mouse IgG and mouse F(ab’)2 (Figure 10). Blocking with 
dog F(ab’)2 had an overall inhibitory effect on signal (P < 0.01), but mouse IgG 
or mouse F(ab’)2 did not have an overall effect on the signal.  
 
 
Figure 10. Thirty-five samples were assayed for IgG anti-F(ab’)2-autoantibodies native and pre-
blocked with 0.5 mg/mL dog F(ab’)2, mouse F(ab’)2 and mouse IgG. There was a significant overall 
effect in replicates blocked with dog F(ab’)2, but not in replicates blocked with mouse IgG nor 
mouse F(ab’)2. 
At a 99.99% prediction interval, dog F(ab’)2 decreased the signal in 35/35 
samples (100%). Anti-F(ab’)2-autoantibodies cross-reacted with mouse IgG in 
3/35 samples (9%) and mouse F(ab’)2 in 3/35 samples (9%). There was no cross-
reactivity to mouse IgG nor to mouse F(ab’)2 in 6/9 samples (67%) with 
previously detected heterophilic antibodies. Three out of 26 samples (12%) 
without previously detected heterophilic antibodies cross-reacted with mouse 
IgG or mouse F(ab’)2. Anti-F(ab’)2-autoreactivity was not significantly higher 
in dog samples reactive with F(ab’)2-fragments of mouse IgG than in samples 
not reactive with F(ab’)2-fragments of mouse IgG. 
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5.1 Screening for anti-mouse antibodies 
 
In paper I, we focused on the bare fundamentals of heterophilic antibodies by 
devising a method that can be used for screening a population for their presence 
and estimate their prevalence. It had already been shown that heterophilic 
antibodies could be found in canine plasma (Solter et al., 2008), but for those 
experiments, pooled plasma was used, preventing prevalence estimations, and 
the technique used only works for canine samples. There was no documentation 
of heterophilic antibodies in cats, another frequently occurring species in 
immunoassay analysis. Nearly all patients that have serum collected at an animal 
hospital are admitted for diagnostic work-up or follow-up. Occasionally, healthy 
animals are sampled at the hospital, for example in theriogenology services, or 
when patients are in complete remission, but the majority of the samples will 
come from animals with some diagnosis or clinical signs of disease. Selecting 
the most recent samples from a diagnostic laboratory, therefore, provides us with 
an appropriate study population for investigating interference, as these animals 
represent those who are most often subjected to immunoassay testing.  
It is important to select an appropriate screening method for heterophilic 
antibodies. There is no gold standard method, nor any commercially available 
test for detecting heterophilic antibodies. In principle, there are two different 
ways of screening for heterophilic antibodies – either directly in each specific 
immunoassay by pre-treating the samples using some method that removes the 
interferents from the sample, or by performing parallel testing with a method 
that detects heterophilic antibodies, often known as an “interference assay” or 
“nonsense assay”. Here, we decided to first screen samples with an interference 
5 Discussion 
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assay, and then to screen positive samples in each specific immunoassay in a 
later study. 
There are different ways to configure an interference assay, but the 
imperative is that it does not detect any specific sample analyte. This objective 
can be achieved by using a mismatched pair of capture and detection antibodies, 
such that they target epitopes that are not found on the same molecule. We used 
polyclonal non-immune mouse IgG for capture and a monoclonal mouse IgG1k 
for detection. The monoclonal antibody is specific for human carcinoembryonic 
antigen (CEA), a molecule not found in dog or cat serum, and at any rate, the 
capture antibody does not recognize human CEA, which therefore prevents 
detection even if CEA were present in the samples. This means that only 
molecules that cross-link mouse IgG, and more specifically, mouse IgG1k, will 
be detected in the assay. In practice, these cross-linking substances are called 
heterophilic antibodies or anti-mouse antibodies. The mouse IgG1k antibody 
was selected because it is the most frequently used antibody in commercial 
immunoassays. Overall, the ELISA protocol was designed to mirror a generic 
immunoassay procedure. However, we did not dilute or incubate the samples in 
any type of blocking buffer resembling a commercial immunoassay, because the 
contents of these are usually unknown. If this had been done, we would likely 
have detected less interference. On the other hand, we would probably have 
detected more interference if we had used a polyclonal mouse IgG for detection, 
and if the samples had been incubated together with the detection antibody in a 
so-called two-step format, which is not uncommon in commercial 
immunoassays.  
Factors such as the selection of cut-off criteria and dilutions of reagents also 
affect the results, and it is well-known that estimated prevalence figures of 
heterophilic antibodies vary greatly depending on these and several other factors. 
The achieved prevalence of 9% in dogs and 5% in cats is, therefore, best seen as 
a rough estimate. The numbers are of less interest than the fact that we were able 
to demonstrate a method for screening for heterophilic antibodies that can be 
used in all species, and that laboratories can use without the need for special 
equipment or custom reagents. This study did not attempt to evaluate the 
usefulness of the method, as that will depend on the specific needs and its 
intended use. It can be used as a parallel screening tool for incoming samples at 
a diagnostic laboratory, for investigating interference in samples with suspected 
interference, or as in this case, for selecting samples of interest for a follow-up 
screening in specific assays. Because of the wide variety of immunoassays and 
configurations of immunoassays that are used in diagnostic laboratories, it is 
perhaps most realistically used as a tool for investigating interference in selected 
samples. The protocol can be modified to match the assay that the sample was 
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previously tested in more closely. For example, if interference is suspected in an 
assay using sheep IgG for capture and monoclonal mouse IgG for detection, the 
capture antibody would be substituted for a non-immune sheep IgG. 
5.2 Interference in commercial hormone immunoassays 
for dogs 
 
Investigating immunoassay interference from heterophilic antibodies is a task 
that is associated with several challenges. One of the major challenges is that the 
correct test result for a patient sample is usually unknown. In the absence of a 
correct result for reference, claims that a test result is incorrect are usually based 
on the perceived plausibility of the result. The starting point for the present 
investigation was a cohort of samples with anti-mouse antibodies and another 
cohort without anti-mouse antibodies. In clinical practice, the starting point for 
an interference investigation is usually a mismatch between the clinical 
presentation and the test result, one of the hallmarks of interference.  
The retrospective nature of this study, which is presented in paper II, means 
that all patient information was limited to second-hand sources in the form of 
medical records. These may not contain the information needed to evaluate the 
plausibility of a particular test result. However, some test results are not intended 
to be interpreted together with an extensive case history and specific clinical 
findings. One example is the anti-Müllerian hormone (AMH) assay, which is, 
among other things, indicated for the determination of neutering status in dogs 
with unknown medical histories. There is no natural source of AMH in neutered 
animals, and detectable serum AMH can, therefore, be attributed to interference. 
The neutering status of the animal is thus all the clinical information needed to 
demonstrate interference in the AMH assay. We considered detectable AMH in 
combination with a medical record documenting the positive neutering status of 
the animal to be evidence for interference. Further, we attributed the source of 
the interference to anti-mouse antibodies if the patient also had a positive test 
result for anti-mouse antibodies. We then blocked interference-positive samples 
with different concentrations of mouse IgG and evaluated the effect of the 
blocking to build a strong chain of circumstantial evidence that endogenous anti-
mouse antibodies altered the test result. Two samples were considered to cause 
interference in the AMH assay as they matched all of these criteria. The clinical 
implications of these findings are that dogs with falsely elevated AMH could be 
subjected to needless surgery if they are incorrectly determined to be unneutered. 
In the two specific cases found here, both dogs were male. In male dogs, needless 
surgery might be performed if the AMH levels falsely indicate bilateral 
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cryptorchidism. However, there is no indication that the sex of the dog has any 
bearing on the probability of interference, and a dog with a false-positive AMH 
result could also be a female with an unknown neutering status.  
The other assays that we investigated were canine TSH, canine TT4 and 
progesterone. In the measurement of these analytes, there is a myriad of factors 
influencing the hormone levels, and the plausibility of the test result cannot be 
reliably inferred from a retrospective source such as a medical record. We 
therefore had to use a method aimed at removing interferents from the samples 
to investigate them for interference, and we selected precipitation with 
polyethylene glycol (PEG) for this purpose. However, because this method has 
not previously been used for canine analytes, there were no established reference 
values for the expected difference in measurements after PEG treatment in 
interference-negative samples. Instead, we defined differences in measurements 
before and after PEG treatment as “discrepant” based on a 99.99% prediction 
interval for the expected result. These calculations are described more 
thoroughly in paper II and the materials and methods section of this thesis. 
Based on several observations, we concluded that the PEG method is not 
useful as a general tool for detecting interference in the immunoassay analysis 
of canine serum. The method did not discriminate between samples with or 
without anti-mouse antibodies, it did not declare any of the tested samples free 
from interference, and the overall incidence of interference with interference 
defined as a discrepancy of more than 4 SD was very high, 73% in samples 
without anti-mouse antibodies. The most plausible explanation for these findings 
is that a fraction of the analytes co-precipitates with the antibodies. This 
observation was noted for all analytes except progesterone. Even if the true 
prevalence of interference in these assays were 73%, it would not be feasible for 
clinicians to re-evaluate the majority of clinical cases, and in many of these 
cases, the discrepancies are not likely to make a difference for the clinical 
interpretation as they do not push the measurement outside of the normal 
reference range. 
5.3 Characterization of canine anti-mouse antibodies 
 
This study was presented in paper III and consisted of two components: first, an 
evaluation of the prevalence of anti-mouse antibodies in two dog breeds. In 
immunometric assays, analytes need to bind both to the capture antibody and the 
detection antibody for a signal to be generated. Therefore, by substituting one of 
the antibodies and keeping all other variables constant, characterization can be 
performed. In this experiment, we put different capture antibodies on the solid 
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phase and kept all other steps of the ELISA procedure intact for all assays. This 
simple principle can be used to characterize binding to different fragments, 
isotypes and subclasses of immunoglobulins, cross-reactivity to 
immunoglobulin from different species, and other antibody properties. The 
limiting factor is essentially the available sample volumes at hand, so we had to 
be selective in deciding which experiments to perform. Here, we took a 
utilitarian approach and prioritized investigating the antibody properties that are 
most likely to impact routine immunoassay analysis. 
One of the most pressing questions about interfering antibodies is which part 
of the target IgG molecule they bind. This knowledge can provide clues to the 
origin of the antibodies – for example, rheumatoid factors are expected to bind 
only the Fc region – but it also gives information that is immediately applicable 
and useful in immunoassay development. The Fc region of IgG is not needed for 
detection of antigen and is in immunoassays only retained for practical purposes, 
as removal of it would entail additional production steps and costs. However, if 
it can be demonstrated that interference through binding to the Fab-region is rare, 
it could motivate the removal of the Fc region as a prophylactic measure against 
interference. Determining the IgG fragment reactivity was, therefore, one of the 
experiments that we decided to perform.  
It is also useful to know if the antibodies are capable of cross-reacting with 
IgG from different species. Although monoclonal mouse IgG is still the default 
antibody in most commercial immunoassays, it is not uncommon for 
immunoassays to use IgG from other species, for example, goat, sheep and 
rabbit, sometimes in combination with mouse IgG. Here it is important to 
remember that the tested samples were pre-selected for their reactivity with 
mouse IgG and that the detection antibody in the assay is a monoclonal mouse 
IgG1k. Thus, putting IgG from different species on the solid phase will only 
detect cross-reactive antibodies, not antibodies that are exclusively anti-goat, 
anti-rabbit, et cetera. 
One of the experiments that cannot be performed with this general principle 
is immunoglobulin isotyping of the endogenous antibodies. By definition, the 
assay will detect anything in the sample capable of bridging two antibodies, and 
therefore also immunoglobulins of all isotypes. Isotyping the endogenous 
antibodies is the most technically challenging experiment in paper III. The most 
critical step is selecting appropriate detection antibodies, which must meet 
several criteria. The first criterion is that they are specific for different 
immunoglobulin isotypes. Secondly, they must not cross-react markedly with 
the mouse IgG that pulls down the interfering antibodies to the solid phase, or 
excessive background will prohibit distinction between isotypes. Moreover, the 
assay is only usable for samples that do not cross-react with goat IgG (all of the 
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detection antibodies are goat IgG), or they will react non-specifically with all the 
detection antibodies, again preventing distinction between isotypes. Because we 
had previously determined the reactivity to goat IgG, we were able to reject the 
samples that reacted with goat IgG for this experiment. 
The results presented in paper III clearly demonstrate that canine anti-mouse 
antibodies are heterogeneous. They can react with IgG from different species, 
with different IgG regions and they can be of the IgA, IgG and IgM isotype. This 
heterogeneity is challenging for laboratories and manufacturers to navigate 
around when attempting to limit the incidence of immunoassay interference. If 
F(ab’)2-fragments are used to capture and detect antigen, there will still be 
antibodies capable of causing interference remaining. The phylogenetic distance 
between two species can probably be used to mitigate interference, as chicken 
IgY for capture and mouse IgG for detection was the combination of antibodies 
that resulted in the least amount of interference. However, this design may not 
work for all purposes, since monoclonal chicken antibodies are currently 
lacking. Monoclonal antibodies are only derived from mammals, and even in a 
small sample cohort, the possibility of cross-reactivity between different 
mammalian IgGs was evident. Because the endogenous antibodies consist of 
several isotypes, removing them from the sample is likely to be impractical. As 
we demonstrated in paper II, antibody precipitation with PEG is a very crude 
method that leads to co-precipitation of several analytes, and the mixture of 
different isotypes precludes the use of isotype-specific methods like Protein A 
and Protein G precipitation for the exclusion of IgG and gel-filtration 
chromatography for IgM. An adequate neutralizing incubation buffer containing 
non-immune IgG is probably the best protection against interference in canine 
samples when all factors are considered, and this is a strategy that both 
manufacturers and diagnostic laboratories can implement. We would also like to 
stress the importance of enhancing the blocking efficiency by heat-treating the 
IgG in this incubation buffer, as was shown in paper II. Although heat-treatment 
requires an extra preparation step, heat-treated incubation buffers can be 
produced in batches and then stored and used in the same way as untreated IgG. 
Interestingly, none of the detected anti-mouse antibodies bound to both Fc- 
and F(ab’)2-fragments, and in some samples, there was only detectable reactivity 
to whole IgG. Selective binding to different IgG fragments is not expected if the 
source of the antibodies is exposure, which we confirmed by showing that anti-
mouse IgG from chickens immunized with whole mouse IgG reacted with both 
Fc- and F(ab’)2-fragments. Instead, it opens up the possibility that the anti-mouse 
antibodies are disease-associated autoantibodies to IgG. It is counterintuitive 
that some samples react with whole IgG but not with either fragment, but this 
might be due to binding on or near the IgG hinge where the digestive enzymes 
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cleave the IgG molecule, possibly altering or removing epitopes in the process. 
These observations paved the way for the final manuscript in the thesis, where 
we elaborated on the clinical significance and the potential origin of the anti-
mouse antibodies. 
5.4 Clinical significance, duration and possible origin of 
canine anti-IgG antibodies 
 
The fourth study, corresponding to manuscript IV, explored the clinical 
significance of heterophilic antibodies against mouse IgG from two different 
angles. First, it was of particular interest to investigate potential connections to 
autoimmune disease and cancer in heterophilic antibodies. Secondly, 
heterophilic antibodies can interfere with therapeutic monoclonal antibodies. 
Both of these scenarios postulate that the heterophilic antibodies are cross-
reactive autoantibodies to IgG. 
We had in paper III observed an increased frequency of heterophilic 
antibodies against F(ab’)2-fragments of mouse IgG in Bernese mountain dogs. 
This breed is not known to be predisposed to autoimmunity, but the mortality 
for cancer in Bernese mountain dogs is around 50% (Klopfenstein et al., 2016). 
It was recently proposed that anti-F(ab’)2-autoantibodies can form in response 
to proteolytic cleavage by cancer-associated proteases (Brezski & Jordan, 2010), 
and previous findings did not indicate that the F(ab’)2-reactive antibodies were 
acquired from exposure to mice. In paper I, we did not find a relationship 
between the presence of heterophilic antibodies and diagnosed cancer, but this 
does not rule out a connection since it is quite possible that these antibodies, if 
they are autoantibodies, appear before disease onset, let alone before a clinical 
diagnosis has been made. 
Two therapeutic monoclonal antibodies are currently approved by regulatory 
agencies for the treatment of cancer in dogs, but nearly 80 therapeutic 
monoclonal antibodies have been approved for use in humans (Lu et al., 2020). 
This discrepancy is due to several factors, but one of them is an incomplete 
understanding of the canine immune system. In drug development, it is vital to 
be able to predict the immunogenicity of a candidate drug. Immunogenicity can 
affect the safety, efficacy and pharmacokinetics of the drug, and the 
development of immunogenic drugs is usually discontinued in the clinical phase, 
after years of basic research and development. Autoantibodies to IgG are a 
source of immunogenicity, and autoantibodies against the Fab region have not 
been described in dogs.  
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We investigated the clinical significance and interconnection of heterophilic 
antibodies and anti-Fab/F(ab’)2-autoantibodies by organizing a prospective 
study, where dog owners contributing samples for paper III were invited to 
respond to a questionnaire about any changes in their dogs’ health status during 
the two years passed since the previous study. Follow-up samples were collected 
and analyzed for heterophilic antibodies to determine their serum duration. We 
tested samples for anti-Fab and anti-F(ab’)2-autoantibodies, and anti-
Fab/F(ab’)2-reactivity was tested for statistical relationships with sex, breed, age, 
health status and presence of heterophilic antibodies. This information helps to 
understand the relationship between heterophilic antibodies and autoantibodies. 
The duration of heterophilic antibodies in serum can guide the clinical handling 
of patients presenting with antibody interference. It can also give clues into the 
origin of the antibodies. The persistent presence of antibodies during two years 
would not be expected if the antibodies are acquired from the often suggested 
fleeting, unknown exposures to antigen (Ismail, 2009; Kazmierczak et al., 2000), 
and might favour the hypothesis that they are autoantibodies associated with 
disease. It is also of relevance to describe the presence of anti-Fab and anti-
F(ab’)2-autoantibodies in dogs for the development of therapeutic monoclonal 
antibodies. 
The results did not show any prospective relationship between the presence 
of heterophilic anti-mouse antibodies and overall disease, nor specific disease 
categories, including cancer. However, it was demonstrated that both anti-Fab 
and anti-F(ab’)2-reactivity is widespread in dogs. The reactivity to F(ab’)2-
fragments was significantly higher than reactivity to Fab-fragments, and there 
was only a low positive correlation between levels of anti-Fab and anti-F(ab’)2-
autoantibodies. This finding suggests that they can bind to mutually exclusive 
cryptic epitopes revealed by enzymatic cleaving in both the lower and the upper 
hinge region. These results have implications for monoclonal antibody 
development in dogs, as anti-Fab and anti-F(ab’)2-autoantibodies can react with 
therapeutic antibodies and affect their safety and efficacy. They can also 
interfere with immunogenicity tests that are used in preclinical and clinical drug 
trials (van Schie et al., 2015).  
There was no connection to cancer or overall disease in samples with 
increased anti-F(ab’)2-autoantibody levels. Thus it seems likely that the lower 
hinge region of canine IgG is of high general antigenicity and that many 
pathways lead to the formation of canine anti-F(ab’)2-autoantibodies. Dogs with 
a clinical disease or clinical signs of disease had significantly increased anti-Fab-
autoantibody levels, which motivates future investigations of disease-associated 
enzymes that might cleave canine IgG in the upper hinge region in vivo. 
Increased anti-Fab-autoantibody levels in people are, for example, associated 
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with squamous-cell carcinomas and adenoid cystic carcinomas of the head and 
neck (Susal et al., 1994). Autoreactivity to the F(ab’)2-region of IgG was not 
statistically increased in samples reactive with F(ab’)2-fragments of mouse IgG 
compared with samples without reactivity to F(ab’)2-fragments of mouse IgG. It 
appears that while all or at least nearly all dogs have some basal level of 
autoreactivity against the F(ab’)2-part of IgG, the increased autoreactivity is not 
directed towards epitopes that are shared with mouse IgG. However, there was 
sporadic cross-reactivity between mouse IgG or mouse F(ab’)2 and anti-F(ab’)2-
autoantibodies (3/35 tested samples), indicating that heterophilic antibodies in 
dogs occasionally may be cross-reactive autoantibodies. There was no evidence 
for exposure to mice being a source of anti-mouse antibodies, as none of the 
dogs belonging to owners reporting observed contact with mice tested positive 
for anti-mouse antibodies. It is possible, though, that the owners had overlooked 
any hypothetical contact with mice. As yet, there is no satisfactory explanation 
for the origin of anti-mouse antibodies in most instances of their presence in 
dogs. 
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The results presented in this thesis add to the basic understanding of heterophilic 
antibodies in veterinary medicine, which remains a largely unexplored research 
field. It could be argued that there are two main paths that future investigations 
can continue along. 
One of the main paths leads to the acquisition of more epidemiological data. 
There is a lot of work remaining when it comes to describing the prevalence of 
heterophilic antibodies in animal species and species breeds. However, the 
presence of heterophilic antibodies does not necessarily equate to immunoassay 
interference. The logical next step is, therefore, to investigate the incidence of 
interference in specific immunoassays of relevance in veterinary medicine. This 
information can serve as a foundation for guidelines and recommendations on 
how a diagnostic laboratory should handle the hazard of antibody interference. 
If the problem is sufficiently common, introducing prophylactic 
countermeasures is a viable course of action, but if it is very sporadic, 
interference is perhaps better dealt with on a case-by-case basis. It would also be 
helpful to identify immunoassays that are especially prone to interference so that 
their use can be discouraged. If alternatives are lacking, it may be difficult to 
discontinue the use of a particular assay, but the importance of putting pressure 
on manufacturers to improve their products must not be neglected. 
There is an ongoing trend in diagnostic medicine that veers towards using 
laboratory tests to identify diseases before the onset of clinical signs, to allow 
for early interventions and a more favourable prognosis. These promises may 
not be compatible with the standards of currently available diagnostic tests. 
Without the possibility to juxtapose test results with clinical findings, most 
analytical errors are initially likely to be overlooked, which by no means equates 
to being irrelevant. For the diagnosing of disease in apparently healthy patients 
to gain wide acceptance, the reliability and performance of the diagnostic tests 
6 Future perspectives 
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would likely need to be impeccable. Achieving these standards will, if at all 
possible, require a substantial amount of research into interference issues. 
Traditionally, laboratory tests have been intended to function as supplementary 
diagnostic tools to support the anamnestic and clinical findings. Yet, many cases 
of interference go unnoticed until after the patient has been misdiagnosed and 
administered the wrong treatment, illustrating that over-reliance on laboratory 
tests does occur and that it can be a harmful habit. There are many options 
available for investigating immunoassay interference, but the initial suspicion 
that a test result is incorrect will often have to come from the clinician and not 
from the laboratory. However, it may not always be realistic to expect clinicians 
to initiate interference investigations. A general lack of awareness of the problem 
is one reason. The interference warnings that immunoassay manufacturers 
frequently include in kit inserts are unlikely to be read by clinicians. It will, 
therefore, be motivated to research heterophilic antibodies in animals for the sole 
purpose of raising the awareness of immunoassay interference in veterinary 
medicine, thereby increasing the probability that more cases are identified. 
However, it must not be forgotten that medical histories and physical 
examinations also are subject to errors and misinterpretations, and it may be 
difficult to identify the missing link when clinical findings and biochemistry 
results are discordant. If a dubious test result is found, there are also several 
differential diagnoses to antibody interference that need to be considered. Here, 
knowledge of the magnitude of the issue with interference will help guide 
clinical decision making. If antibody interference is common, it would 
presumably be placed high on a list of potential causes for a questionable test 
result. If it is exceedingly rare, it may be worthwhile first to consider alternative 
explanations, which may include uncommon but legitimate medical causes. An 
example from human medicine is thyrotropinoma, a pituitary tumour with the 
same clinical manifestation as hyperthyroidism, but which causes raised TSH 
coupled with raised T3 and T4. This atypical combination would run a high risk 
of being dismissed as erroneous on analytical grounds, representing a scenario 
where a habit of questioning test results may instead lead to a missed or delayed 
diagnosis. Although knowing the incidence rate of interference is important in 
order to make informed clinical decisions, it is still valuable to merely 
demonstrate the existence of clinically relevant immunoassay interference in a 
species or a particular immunoassay regardless of its incidence. Even a low 
incidence rate could amount to a high total number of cases, and the outcome in 
each case is potentially devastating when patient safety is at risk.  
Immunoassay interference is also an issue of relevance when veterinary care 
is less centred around individual animals. In the livestock sector, immunoassays 
are often used for active or passive surveillance of diseases with major socio-
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economic impact. Avian influenza, brucellosis, leptospirosis and Q fever are 
some examples of zoonotic diseases that in Sweden are surveilled at least partly 
with immunodiagnostic methods. The rigour of the surveillance ultimately 
determines the potential consequences of immunoassay interference. It is well-
known that immunoassays and other diagnostic methods all have their 
limitations and performance issues, which is why several laboratory tests often 
are used in combination to confirm the diagnosis of a surveilled disease. 
Nevertheless, a false-positive test result due to immunoassay interference is one 
step towards an incorrect estimate of the prevalence of the disease, which should 
be especially concerning when it comes to diseases that are considered to be 
eradicated in the surveilled area. Veterinarians and researchers also use 
immunoassays to analyze specimens from wild animals for a variety of purposes, 
including disease surveillance and monitoring of reproductive activity. Wild 
animals are likely to be exposed to animal species that are used to raise 
immunoassay antibodies, and although very little is known about autoimmunity 
in wild animals, it was recently shown that autoantibodies are widespread in 
unmanaged sheep (Graham et al., 2010). 
Dogs are receiving increasing attention as models for studying cancer in 
humans (DeWeerdt, 2018), as well as recipients of novel immunotherapies 
(Ledford, 2016), even though a significant influx of monoclonal antibody drugs 
for dogs is still some distance away (Klingemann, 2018). However, if this 
development continues, it will open up a whole new avenue of investigation 
regarding canine anti-IgG antibodies. If monoclonal antibody therapies become 
widely available for dogs, the potential threat of immunoassay interference due 
to iatrogenic anti-mouse antibodies may be one of the lesser worries, as long as 
the therapeutic antibodies are speciated. However, autoantibodies against IgG 
can contribute to the immunogenicity of speciated therapeutic antibodies. 
Although efforts to develop novel veterinary treatments are laudable, it is 
disconcerting that therapeutic antibodies for dogs and cats are currently in the 
clinical pipeline when a basic understanding of factors that could influence the 
safety and efficacy of antibody therapies in these species is lacking. An 
inventory of pre-existing anti-IgG antibodies in dogs is much needed, as these 
antibodies could affect the immunogenicity of future antibody therapies. These 
pre-existing antibodies include rheumatoid factors, anti-idiotypic antibodies and 
anti-Fab/F(ab’)2-autoantibodies, most of which have been poorly studied in dogs 
to date. These anti-immunoglobulin antibodies could also interfere with the 
immunogenicity assays that are used in drug development to monitor treatment 
response (van Schie et al., 2015). Lack of knowledge about such pre-existing 
antibodies is not only a concern for future immunotherapies but also one of many 
factors currently holding back their development. The existence of pre-existing 
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anti-IgG antibodies has not even been investigated for current treatments, and it 
is possible that canine anti-equine and anti-sheep antibodies are a source of early 
adverse reactions to antivenom administration following snake bites, as has been 
suggested in humans (Herrera et al., 2005).  
The second main path of research on heterophilic antibodies goes deeper into 
the immunological mechanisms and the molecular and biochemical interactions 
underlying interference. This field is relatively unexplored also in human 
medicine. The majority of endogenous antibodies causing interference are 
poorly defined. Multifaceted antibodies of a potentially wide variety of origins 
are lumped together, the only common denominators being that they cause 
interference and that their source is unknown. Because many of the publications 
on heterophilic antibodies are case reports, accounts of their origin are often 
anecdotic. Screening studies have yielded such high prevalence figures of 
heterophilic antibodies that there is reason to suspect that they are more or less 
ubiquitous in the human population, and it is not unthinkable that the same 
applies to other species. If that is the case, future research should focus on 
investigating specific sources and characteristics of these antibodies. Besides the 
well-known rheumatoid factors, there are other possible links between 
interfering antibodies and disease mechanisms. These might extend beyond the 
classic examples of autoimmune diseases. For example, cancers with a high 
mutational burden are immunogenic and could induce the formation of broadly 
reactive antibodies to neo-epitopes on tumour cell surfaces. These could 
interfere with immunoassays through a mechanism analogous to antibodies 
directed against surface epitopes on E. coli bacteria (Covinsky et al., 2000). In 
this thesis, we investigated a potential connection between immunoassay 
interference, anti-F(ab’)2-autoantibodies and cancer. Although there was 
ultimately no evidence for a connection, it is a field of investigation that deserves 
further exploration. Investigating connections between severe disease and 
interfering antibodies makes double sense because if there is a link between a 
particular disease and interference, the risk for interference increases not only 
due to the link itself but also because more tests are presumably run on the 
patient for diagnostic and post-diagnostic management. 
If there is a connection between heterophilic antibodies and disease, there 
might also be opportunities to use the antibodies as prognostic or diagnostic 
markers for disease. Rheumatoid factor detection in rheumatoid arthritis is not 
the only scenario when an interfering antibody might have diagnostic value. 
There is also a medical condition called cryoglobulinemia, which is associated 
with several causes, including hepatitis C viral infection in people. 
Cryoglobulins are immune complexes consisting of rheumatoid factors and 
polyclonal IgG that associate with the core protein of the hepatitis C virus. 
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Testing for cryoglobulins could be valuable for diagnosing hepatitis C, although 
it is rarely performed in practice (Shihabi, 2006). Hepatitis C infection is not 
known to occur in animals, but cryoglobulinemia is sporadically observed in 
dogs and cats with multiple myeloma (Giraudel et al., 2002; Hickford et al., 
2000). 
It is important to recognize that in vitro conditions are different from in vivo 
conditions and that knowledge about interactions taking place within organisms 
is not necessarily applicable to interactions in a microtiter well. Immunoassays 
require immobilization of antibodies or antigen on a solid phase, which is a 
complex reaction involving hydrophobic and electrostatic interactions. In this 
process, capture antibodies can be denatured and randomly oriented (Butler et 
al., 1993), predetermining which epitopes become available for binding. When 
coating a microtiter well, the solid phase is overflown with molecules, 
sometimes forming layers of antibodies held together by weak electrostatic 
interactions. It has been suggested that these stochastic events can form 
repetitive epitopes on the solid phase that low-affinity endogenous antibodies 
can initiate interactions with, even though these interactions do not happen in 
vivo (Bjerner et al., 2005). Similarly, human IgG4 can bind to the Fc region of 
immobilized antibodies with its own Fc region (Rispens et al., 2009), an 
interaction presumed to be exclusive to in vitro conditions. However, these 
fundamentals of immunoassay analysis remain poorly understood. It has been 
stated that in the current era of immunoassays, “the technological cart is before 
the scientific horse” (Qian et al., 2000). In fact, that was the case from the 
beginning; as a technology utilizing animal antibodies to measure proteins and 
peptides, immunoassays received widespread use over a decade before it was 
understood how nature had been making these antibodies for millions of years 
to fight parasites, bacteria, viruses and other pathogens (Tonegawa et al., 1974). 
Today, immunoassays are routinely used to measure non-immunogenic small 
molecules like steroid hormones, requiring laborious conjugation and 
modification of steroid structures. Waves of different antibody types, labels and 
engineering techniques have come and gone, but limitations in assay 
performances remain. Laboratories and clinics are using immunoassays to 
diagnose diseases in species for which the assay was not designed nor validated. 
Critics are claiming that immunoassays have been pushed past their limits and 
that it is time for diagnostic laboratories to phase out immunoassays, starting 
with steroid hormone assays (Taylor et al., 2015), and move on to mass 
spectrometry. However, this transition would not be without complications 
(Auchus, 2014), and it seems likely that we will continue to use immunoassays 
in clinical diagnostics for the foreseeable future. Meanwhile, the search for 
clinically useful biomarkers is going deeper into the lower end of the plasma 
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proteome, requiring increasingly sensitive methods (Landegren et al., 2012) for 
the detection of low-concentration molecules. In this process, it is crucial to keep 
in mind the limitations of the methods used to detect candidate biomarkers, 
whether immunoassays or otherwise, and to also investigate the interference 
issues associated with highly sensitive detection methods. 
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 Heterophilic antibodies reactive with mouse IgG are detectable using a 
species-independent assay in 9% of dogs and 5% of cats admitted to an 
animal hospital. 
 Canine anti‐mouse antibodies are a source of erroneous results in 
immunoassay analysis of anti-Müllerian hormone (AMH). 
 Antibody precipitation with PEG is not a useful tool for detecting antibody 
interference in hormone immunoassays for canine samples. 
 Canine anti-mouse antibodies can be of the IgA, IgG and IgM isotype, are 
capable of cross-reacting with IgG from several species and target both Fc- 
and F(ab’)2-fragments of mouse IgG. 
 There are individual differences in the properties of canine anti-mouse 
antibodies, and the prevalence differs between dog breeds. 
 Canine heterophilic antibodies against mouse IgG can persist in serum for at 
least two years. 
 Anti-Fab and anti-F(ab’)2-autoantibodies reactive with cryptic epitopes in the 
hinge region of IgG are commonly found in dogs and can sporadically cross-
react with mouse IgG. 
  
7 Conclusions 
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Immunoassays play a crucial role in modern medicine. The technology uses 
target-seeking animal antibodies to detect and measure specific molecules in 
biological samples. For more than 60 years, this method has been used to guide 
the diagnosis of patients with disease. The reliance on animal antibodies comes 
with a drawback: they can themselves become targets for anti-animal antibodies, 
often called heterophilic antibodies, causing false test results. In the worst case, 
this leads to the patient receiving the wrong diagnosis and medical treatment. 
Very little is known about this problem in veterinary medicine. In this thesis, 
we aimed to add some basic information about heterophilic antibodies in 
animals, with the main focus on dogs. The overarching aims were to investigate 
their prevalence, their impact on diagnostic tests, some of their molecular 
characteristics and their potential origins. We conceived a method for detecting 
these antibodies and estimated a prevalence of 9% in dog patients and 5% in cat 
patients. It was found that the detected antibodies can affect measurements of 
anti-Müllerian hormone (AMH), which could subject patients to, for example, 
needless surgery. There was a broad diversity in the characteristics of the 
antibodies, a major obstacle for eliminating their effects on diagnostic tests. The 
origins of the antibodies remain unknown, but they can likely be acquired from 
a variety of sources, and they appear to be more frequent in certain dog breeds, 
including the Bernese mountain dog. We found that the antibodies can persist 
for at least two years in dogs, which is a risk factor for repeated analytical errors 
and misdiagnosis in dogs with heterophilic antibodies.  
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Immunanalyser spelar en nyckelroll inom dagens sjukvård. Tekniken använder 
sig av målsökande djurantikroppar för att detektera och mäta specifika 
molekyler i patientprover. I mer än 60 år har dessa metoder använts för att 
diagnostisera sjukdomar. Trots detta är metoderna inte felfria. Bland annat så 
kan de djurantikroppar som tekniken använder sig av bli måltavlor för 
cirkulerande anti-djurantikroppar hos patienter, även kallade heterofila 
antikroppar, vilket kan orsaka felaktiga provsvar. I värsta fall blir följden att 
patienten får fel diagnos och fel medicinsk behandling. 
Inom veterinärmedicin är kunskapen om detta problem mycket begränsad. 
Syftet med den här avhandlingen var att undersöka grundläggande egenskaper 
hos heterofila antikroppar hos djur, med huvudfokus på hund. De övergripande 
målsättningarna var att undersöka deras förekomst, deras påverkan på 
diagnostiska test, några av deras molekylära egenskaper och deras tänkbara 
ursprung. Vi utvecklade en metod för att detektera dessa antikroppar och 
uppskattade förekomsten till 9 % hos hundpatienter och 5 % hos kattpatienter. 
Antikropparna visade sig ha förmåga att påverka mätningar av anti-müllerskt 
hormon (AMH), vilket kan få till följd att patienter utsätts för kirurgiska ingrepp 
i onödan. Det fanns en bred variation av molekylära egenskaper hos 
antikropparna, vilket försvårar arbetet med att förhindra deras påverkan på 
diagnostiska test. Antikropparnas ursprung är alltjämt okänd, men sannolikt 
finns det flera olika källor till deras uppkomst och det finns en variation i deras 
förekomst mellan olika hundraser. Vi visade att antikropparna kan kvarstå 
åtminstone två år i cirkulationen hos hundar, vilket är en riskfaktor för upprepade 
felaktiga testresultat och diagnoser hos hundar som har dessa antikroppar. 
 
 
Populärvetenskaplig sammanfattning 
73 
 
 
My main advisor Bodil Ström Holst – thank you for entrusting me with this 
challenging and exciting project, for making it easy to share ideas, and for 
making sure that no sloppy phrasings slipped through the cracks. I have learned 
a lot about how research gets made during these years. Out of all metaphors, I 
like to think of the PhD journey as a tightrope walk; the key is not looking down, 
and thanks to all the interesting leads we had, there was hardly any time for 
looking down. 
 
Helene Hamlin – for valuing the clear communication of science, for being a 
reliable source of optimism and constructive feedback, and not least, for being 
the voice of reason during the occasional heated argument.  
 
Anders Larsson – for always throwing out a myriad of ideas and questions at a 
tireless pace during our meetings. Sometimes we came prepared, and sometimes 
we winged it, but I never left without a head spinning with thoughts. 
 
In many ways, this story took its first turn eight years ago when my 
undergraduate supervisor Wilhelm “Wille” Engström convinced me that my 
bachelor’s thesis could be turned into a review paper. I can admit now that I 
found it crazy and intimidating at the time, but it worked, and it was a turning 
point in my life. Then when I went to the UK and did my first experimental work 
of my own for my master thesis, Kim Moorwood and Andrew Ward further 
helped me carve out my future by installing some healthy scepticism in my naïve 
scientific mind. 
 
Despite not being a clinical pathologist by training, I have during this time 
always felt like a part of this exclusive niche of veterinary medicine. Thank you 
for always being helpful and for the great congress memories: Inger Lilliehöök, 
Acknowledgements 
74 
 
Harold Tvedten, Ulrika Falkenö, Sofia Hanås, Sarah Jensen, Anna Selin, 
Ninni Rothlin Zachrisson, my intermittent office mates Helena Pettersson, 
Emma Strage and for a brief while in the beginning, Anna Hillström, who 
offered me the excellent advice to get a dog during my PhD. In saying this, I 
have to give special thanks to the head of the clinical pathology lab Eva Molin, 
who repeatedly bailed me out by taking said dog out for lunch walks when I was 
taking PhD courses at other universities. Also, a special recognition to Andrine 
who I feel might have gone a little bit beyond the calls of duty to coordinate the 
analysis of hundreds of samples for paper II. 
 
Most of the experiments in this thesis were performed at the KV lab, where I 
was always greeted by the hospitality and assistance of co-author of the first 
paper Anna Svensson and Guo, Annika, Gabriella, Haleh and others. Thank 
you and sorry for clogging up your freezers with all my assorted samples. 
 
Two of the manuscripts herein would not have seen the light of day without the 
contributions from the talented veterinary students that I have been fortunate to 
supervise. I wish you the best of luck, Emma Åhlén and Camilla Bäckström. 
To my colleague in China Bo Dong: it was very nice to have you here in Sweden 
for a year and I hope that some sort of collaboration can come to fruition in the 
future. 
 
The PhD council was a big part of my PhD education and the place where I met 
Anja, Emma, Hanna, Julie, Torun, Hadrien, Niclas, Pontus, Todd and many 
others in the different boards and committees. I’d like to think that we made 
some kind of difference as we waded through an endless stream of guidelines, 
surveys, quality assurances and all kinds of administrative driftwood… at least 
it was more “FUN” than I could have imagined. 
 
Thank you Ylva Sjunnesson for being a great director of PhD studies and for 
bringing me along to something like 30 start meetings. Now I know all there is 
to know about starting up your PhD studies at SLU. 
 
I had a great time being part of the writing and statistics groups with Lena-Mari, 
Ida, Lisa, Dorota, Josef, Karolina, Emeli, Gunilla and Karin. It was a 
nostalgic feeling to study in groups and cram for exams once again! 
 
I have not forgotten my early PhD days when the corridors were filled with 
coffee-loving senior colleagues such as Hanna, Malin Ö, Jenny, Sanna, Malin 
H-G, Axel, Annette, Elin M, Anna and Elin G.  
75 
 
Thanks to The Centre for Reproductive Biology in Uppsala (CRU) for 
organizing some great postgraduate activities and inviting me to present my 
research at seminars and meetings. 
 
Thank you to all the friends and colleagues who made those years in vet school 
so memorable and endurable, including David, Viktor, and all the other guys 
from the “back row” that I haven’t seen in far too long now. Christian, I hope 
you are resting peacefully in NZ soil. 
 
I am grateful to my colleagues at Livsmedelsverket who enabled me to get up to 
those stunning mountains and see some (stunned…) reindeer in winter while 
moonlighting as a veterinary inspector during the seasonal reindeer slaughter. 
 
My friends and past and present neighbours in Eriksberg: Björn, Håkan, Johan, 
Moa, Erik, Cecilia, Malin, Eliška, Daniel, Amanda for giving me a break from 
all the veterinary stuff for more than ten years now. 
 
This project would not have been possible without the help from funders and pet 
owners who recognize the value of companion animal research. Thank you to 
Svenska djurskyddsföreningen, Agria och SKK forskningsfond, Jan 
Skogsborgs stiftelse, Thure F. och Karin Forsbergs stiftelse and hundreds of 
dog and cat owners who have been so generous with their consent and time to 
donate samples to our studies (I trust you that this consent extends to the dogs 
and cats themselves). 
 
As I am typing these words, it is well past midnight, and I am running out of 
midnight oil to burn. So I will hurry to the finish line and give a joint thank you 
to all of the non-name-dropped fellow PhD students and colleagues that I have 
met at courses, conferences, in the corridors or at start meetings with Ylva. You 
are simply too many to mention, but I hope to be able to celebrate with you when 
the COVID pandemic is over! 
 
I just cannot stop without acknowledging my dog Rufus and cat Zelda for 
keeping me in check and forcing me to take my eyes off the computer screen 
when working at home. 
 
Last but not least, I am forever grateful to my family – Mom, Dad, brother and 
sisters for teaching me to read and write as a young lad and for all the support 
and affection that I have received over the years. 
 
!CTA 5NIVERSITATIS !GRICULTURAE 3UECIAE
Acta Universitatis Agriculturae Sueciae
Doctoral Thesis No. 2020:22
Heterophilic antibodies interfere with immunoassays and cause analytical errors. 
The results presented herein elaborate on the prevalence, clinical impact, molecular 
characteristics and potential origin of heterophilic antibodies in dogs. It is demonstrated 
that canine heterophilic antibodies can cause incorrect measurements of anti-Müllerian 
hormone, with the following risk for misdiagnosis in patients. The antibodies are 
heterogeneous in characteristics and persistent for at least two years in circulation, 
making them difficult for laboratories, clinicians and test manufacturers to navigate around.
Daniel Bergman received his postgraduate education at the Department of Clinical 
Sciences. His veterinary degree was obtained at the Swedish University of Agricultural 
Sciences (SLU).
Acta Universitatis Agriculturae Sueciae presents doctoral theses from the Swedish 
University of Agricultural Sciences (SLU).
SLU generates knowledge for the sustainable use of biological natural resources. 
Research, education, extension, as well as environmental monitoring and assessment 
are used to achieve this goal.
Online publication of thesis summary: http://pub.epsilon.slu.se/
ISSN 1652-6880
ISBN (print version) 978-91-7760-562-1 
ISBN (electronic version) 978-91-7760-563-8
Doctoral Thesis No. 2020:22
Faculty of Veterinary Medicine and Animal Science
D
octoral T
h
esis N
o. 2020:22  •  C
anine heterophilic antibodies   •  D
aniel B
ergm
an
Canine heterophilic antibodies
Daniel Bergman
